Stabilization of (r)-ruxolitinib

Abstract

The present disclosure relates to pharmaceutical compositions comprising a pharmaceutically active compound or a pharmaceutically acceptable salt thereof dissolved or suspended in a vehicle comprising a semifluorinated alkane.

Description

[0001]NVL24P01PC1 STABILIZATION^OF^ACTIVE^COMPOUNDS Description BACKGROUND The stability of an active pharmaceutical compound during storage over a variety of conditions is a generally of concern during development of a formulation for the compound. This aspect is especially relevant for liquid formulations of isomerizable pharmaceutically active compounds, as the isomerization processes will result in structural changes to the compound which can have significant impact on its properties, including its pharmacologicalproperties and pharmacokinetic profile.For example, with enantiomeric compounds it may often be the case that only one of a pair ofenantiomers may be active or provide a desired pharmacological effect, while the otherenantiomer is less active, or even harmful. For some active drug compounds however, theremay also be significant differences in physiological activity between the two enantiomers; forexample, one enantiomer has pharmacological activity, while the other exhibits significantdrug toxicity characteristics to the extent that it may be unsafe for clinical use.Thus for drug product formulations comprising only one, or predominantly only one isomer, such as a single enantiomer of an active compound, it is not only important that the compound integrity is maintained and degradation of the compound is avoided or minimized in storage, but also that there is no loss or change in stereochemical purity of the compound in the composition.It is thus an object of the present disclosure to provide a composition, in particular liquidcompositions, comprising an isomerizable compound e.g. an enantiomer of a compound,which improves the stability of said active compound in particular during storage, but is alsodirectly applicable for therapeutic use, such as for topical ophthalmic administration. Further objects will be clear on the basis of the following description, examples and claims. SUMMARY OF THE DISCLOSUREIn one aspect, the present disclosure provides for pharmaceutical composition comprising apharmaceutically active compound as disclosed herein or a pharmaceutically acceptable saltthereof, wherein the pharmaceutically active compound is dissolved or suspended in avehicle comprising a semifluorinated alkane and optionally one or more excipients; wherein the semifluorinated alkane is selected from F4H5, F4H6, F6H4, F6H6, F6H8, F6H10, the structural isomers of these semifluorinated alkanes or any combination thereof. The present disclosure also relates to methods for stabilizing a pharmaceutically active compound asdisclosed herein or a pharmaceutically acceptable salt thereof in a composition, the methodcomprising a step of dissolving the pharmaceutically active compound in a semifluorinatedalkane. In yet a further aspect, the disclosure also provides for the use of these pharmaceutical compositions, e.g. for use as a medicine such as for the treatment of ophthalmological conditions or disorders. In a further aspect, the disclosure relates to a liquid pharmaceutical composition comprising an enantiomer of a pharmaceutically active compound or a pharmaceutically acceptable saltthereof, wherein the enantiomer is dissolved or suspended in a semifluorinated alkane, ordissolved or suspended in a vehicle comprising of a semifluorinated alkane and one or more excipients. The enantiomer is present in the composition in an enantiomeric excess of at least 78%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 93%, 96%, 97%, 98% or 99%. The present disclosure also relates to methods for stabilizing, or preventing, or reducing the loss (e.g. of enantiomeric excess, or enantiomeric purity) of an enantiomer of a pharmaceutically active compound, or its pharmaceutically acceptable salt in a liquid composition. DESCRIPTION OF THE DRAWINGS Figure 1 depicts an HPLC chromatograph obtained for a composition comprising 0.1 mg / mL(S)-hyoscyamine in F4H5, the composition comprising an enantiomeric excess of 81.6% of(S)-hyoscyamine (an enantiomeric ratio of 9.87, of (S)-hyoscyamine to (R)-hyoscyamine).DETAILED DESCRIPTION OF THE DISCLOSUREIn a first aspect, the present disclosure relates to a pharmaceutical composition comprising apharmaceutically active compound selected from the list consisting of the compounds 2a to76a featured in Column A, or compounds 2b to 76b featured in Column B of Table 1 asreferenced below or a pharmaceutically acceptable salt thereof, wherein thepharmaceutically active compound is dissolved or suspended in a vehicle comprising asemifluorinated alkane and optionally one or more excipients. The semifluorinated alkane isin one embodiment, F4H5, F4H6, F6H4, F6H6, F6H8, F6H10, the structural isomers of thesesemifluorinated alkanes or any combination or mixtures of these compounds. Preferably, saidcompositions are liquid compositions.In another aspect, the present disclosure relates to a pharmaceutical composition comprisingan isomerizable pharmaceutically active compound selected from the list consisting of the compounds 2a to 76a featured in the Column A, or from the list consisting of compounds 2bto 76b featured in the Column B in Table 1 as referenced below, or a pharmaceuticallyacceptable salt thereof dissolved or suspended in a vehicle comprising a semifluorinated alkane. The isomerizable pharmaceutically active compound is preferably a compound which comprises at least one chiral stereocenter. In one embodiment, the compound comprises one chiral stereocenter. Said compound may be one of a pair of stereoisomers, e.g. an enantiomer.In other embodiments, the isomerizable compound according to the present disclosure maycomprise more than one chiral stereocenter. In other embodiments, the compound may be a diastereomer. In particular, the chiral stereocenter may be one that is labile, or susceptible to racemization, or inversion, or in the case the compound is a diastereomeric compound, prone to epimerization at one of its chiral stereocenters. In one embodiment, the chiral stereocenter is on an acidic or basic carbon.In a related aspect, the present disclosure relates to a liquid pharmaceutical compositioncomprising an enantiomer of a pharmaceutically active compound or a pharmaceutically acceptable salt thereof, wherein the enantiomer is present in the composition in an enantiomeric excess of at least 78%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 93%, 96%, 97%, 98% or 99%, and wherein the enantiomer is dissolved or suspended in a semifluorinated alkane, or dissolved or suspended in a vehicle comprising of a semifluorinated alkane and one or more excipients. Enantiomeric excess (ee) is a measurement of purity used for chiral substances. It reflects thedegree to which a sample contains one enantiomer (e.g. (S)-abediterol (2a) in reference to thelist of enantiomeric compounds in Table 1 below) in greater amounts than its mirror imagestereoisomer (e.g. (R)- abediterol, (2b) in reference to the list of enantiomeric compounds inTable 1 below). A racemic mixture has an ee of 0%, while a single completely pureenantiomer (e.g. an enantiopure compound) has an ee of 100%. A sample with 70% of (S)-abediterol (2a) and 30% of (R)-abediterol (2b) has an ee of 40% (70% − 30%).In another aspect, the present disclosure relates to a liquid pharmaceutical compositioncomprising enantiomers of a pharmaceutically active compound or a pharmaceutically acceptable salt thereof, wherein the ratio of the first enantiomer relative to the secondenantiomer is at least 89:11, 90:10, 91:8, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 or at least99:1, wherein the enantiomer or enantiomers are dissolved or suspended in a semifluorinated alkane; or are dissolved or suspended in a vehicle comprising a semifluorinated alkane and one or more excipients. As understood herein, a liquid pharmaceutical composition comprising enantiomers of a pharmaceutically active compound, or a pharmaceutically acceptable salt thereof refers to a composition that comprises a pair of enantiomers of the same compound which are mirrorimage stereoisomers. The enantiopurity or stereochemical purity of the compound reflectingthe extent or the amount of an enantiomer or a stereoisomer e.g. in a sample of thecompound, or in the composition may be defined or expressed for example by ratios (i.e.enantiomeric ratios), or the enantiomeric excess (ee) as defined herein. In someembodiments, said compound according to the present disclosure comprises one chiral stereo center. In some embodiments, the compound comprises a chiral stereocenter on a carbon atom, wherein at least one of the substituents of the chiral stereocenter is i) a hydrogen moiety prone to deprotonation under basic conditions and / or ii) is an alcohol moiety prone to dehydration under acidic conditions.With respect to the enantiomer of a pharmaceutically active compound which are featured inthe compositions according to the present disclosure, these may be selected from the listconsisting of the compounds 2a to 76a featured in the Column A, or compounds 2b to 76bfeatured in the Column B in Table 1 below.Table 1 Column^A Column^BNo. Compound No. Compound1a (S)-hyoscyamine 1b (R)-hyoscyamine2a (S)-abediterol 2b (R)-abediterol3a (R)-albuterol (levalbuterol) 3b (S)-albuterol4a (S)-amlodipine (levamlodipine) 4b (R)-amlodipine5a levoamphetamine 5b dextroamphetamine6a (S)-atomoxetine 6b (R)-atomoxetine7a levobetaxolol ((S)-betaxolol) 7b (R)-betaxolol8a (R)-bicalutamide 8b (S)-bicalutamide9a levobunolol 9b dextrobunololColumn^A Column^BNo. Compound No. Compounda (S)-bupivacaine 10b (R)-bupivacaine(levbupivacaine)a levocabastine 11b dextrocabastinea (S)-carteolol 12b (R)-carteolola levocetirizin 13b dextrocetirizina dexchlorpheniramine 14b (-)-chlorpheniraminea (S)-chlorpheniramine 15b (R)-chlorpheniramine(dexchlorpheniramine)a (S)-citalopram (escitalopram) 16b (R)-citaloprama (S)-cromoglicic acid 17b (R)-cromoglicic acida (S)-dipivefrine 18b (R)-dipivefrinea (-)-dobutamine 19b (+)-dobutaminea (R)-doxylamine 20b (S)-doxylaminea (S)-duloxetine 21b (R)-duloxetinea (-)-erythro-mefloquin 22b (+)-erythro-mefloquina levoketoconazole 23b dextroketoconazolea dexfenfluramine 24b levofenfluraminea (R)-fenoldopam 25b (S)-fenoldopama (-)-gusperimus 26b (+)-gusperimus(deoxyspergualin)a (R)-lansoprazole 27b (S)-lansoprazole(dexlansoprazole)a (S)-lenalidomide 28b (R)-lenalidomidea levoleucovorin 29b dexleucovorina linezolid (S-isomer) 30b (R)-linezolida (R)-lipoic acid 31b (S)-lipoic acida (R)-mebeverine 32b (S)-mebeverinea dexmedetomidine 33b levomedetomidinea levomethadone 34b dexmethadonea L-methamphetamine 35b D-methamphetamine(levmetamfetamine) (dextromethamphetamine)a (S)-methotrexate 36b (R)-methotrexatea D-methylphenidate 37b L-methylphenidate(dexmethylphenidate)a (S)-metipranolol 38b (R)-metipranolola L-milnacipran 39b D-milnacipran(levomilnacipran) (levomilnacipran)a (R)-modafinil) (armodafinil) 40b (S)-modafinila (S)-naproxen 41b (R)-naproxena levonorgestrel 42b dexnorgestrelColumn^A Column^BNo. Compound No. Compounda (S)-omeprazole 43b (R)-omeprazole(esomeprazole)a L-ormeloxifene 44b D-ormeloxifene(levormeloxifene)a levoprotiline 45b dextroprotilinea (R)-oxybutynin 46b (S)-oxybutynina dexpanthenol 47b levopanthenola (S)-pheniramine malleate 48b (R)-pheniramine malleatea (S)-pindolol 49b (R)-pindolola (R)-pioglitazone 50b (S)-pioglitazonea (R)-pralatrexate 51b (S)-pralatrexatea (S)-procyclidine 52b (R)-procyclidinea levo-epinephrine 53b dextro-epinephrinea ropivacaine (S-isomer) 54b (R)-ropivacainea (-)-rotigotine 55b (+)-rotigotinea (R)-ruxolitinib 56b (S)-ruxolitiniba (R)-salbutamol 57b (S)-salbutamol(levosalbutamol)a L-scopolamine 58b D-scopolaminea (R)-tedizolid 59b (S)-tedizolida (R)-thalidomide 60b (S)-thalidomidea (+)-tramadol 61b (-)-tramadola (+)-tranylcypromine 62b (-)-tranylcyprominea (-)-trihexylphenidyl 63b (+)-trihexylphenidyla (R)-tropicamide 64b (S)-tropicamidea (S)-valsartan 65b (R)-valsartana L-verapamil 66b D-verapamila (S)-vigabatrin 67b (R)-vigabatrina (S)-warfarin 68b (R)-warfarina (S)-zopiclone (eszoplicone) 69b (R)-zopiclone (eszoplicone)a (R)-STX478 70b (S)-STX478a (2R,5S)-ritlecitinib 71b (2S,5R)-ritlecitiniba (3S,4R)-delgocitinib 72b (3R,4S)-delgocitiniba (3R,4R)-tofacitinib 73b (3S,4S)-tofacitiniba 4-[(1R)-1-Phenylethyl]-1,3- 74b 4-[(1S)-1-Phenylethyl]-1,3-benzenediol benzenediola (2S)-3-phenyl-2-(undec-10- 75b (2R)-3-phenyl-2-(undec-10-enoylamino)propanoic acid enoylamino)propanoic acida (S)-equol 76b (R)-equol(R)-STX478 is N-(2-Amino-5-pyrimidinyl)-N′-[(1R)-1-(5,7-difluoro-3-methyl-2-benzofuranyl)-2,2,2-trifluoroethyl]urea, and (S)-STX478 is N-(2-Amino-5-pyrimidinyl)-N′-[(1S)-1-(5,7-difluoro-3-methyl-2-benzofuranyl)-2,2,2-trifluoroethyl]urea.(2R,5S)-ritlecitinib is 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one and (2S,5R)-ritlecitinib is 1-[(2R,5S)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one.(3S, 4R)-delgocitinib is 3-[(3S,4R)-3-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]oct-1-yl]-3-oxopropanenitrile and (3R, 4S)-delgocitinib is 3-[(3R,4S)-3-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]oct-1-yl]-3- oxopropanenitrile.(3R, 4R)-tofacitinib is 3-{(3R,4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile and (3S, 4S)-tofacitinib is 3-{(3S,4S)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile. With respect to a pair of enantiomers (first or second enantiomer) the compounds in columnA may be referred to as the first enantiomer (2a to 76a), and the compounds in Column B asthe second enantiomer (2b to 76b) of the enantiomer pair, however the ‘first’ and ‘second’designations may also be used interchangeably, i.e. depending on context. In someembodiments, the liquid pharmaceutical composition comprises enantiomers of apharmaceutically active compound or a pharmaceutically acceptable salt thereof selectedfrom any row of Table 1, wherein the ratio of the first enantiomer (column A; 2a to 76a)relative to the second enantiomer (column B; 2b to 76b) is at least 89:11, 90:10, 91:8, 92:8,93:7, 94:6, 95:5, 96:4, 97:3, 98:2 or at least 99:1, wherein the enantiomers are dissolved or suspended in a semifluorinated alkane; or are dissolved or suspended in a vehicle comprisinga semifluorinated alkane and one or more excipients. In other embodiments, the liquidpharmaceutical composition comprises enantiomers of a pharmaceutically active compoundor a pharmaceutically acceptable salt thereof selected from any row of Table 1, wherein theratio of the enantiomer in column B, 2b to 76b, relative to its enantiomer in column A, 2a to76a, is at least 89:11, 90:10, 91:8, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 or at least 99:1,wherein the enantiomers are dissolved or suspended in a semifluorinated alkane; or are dissolved or suspended in a vehicle comprising a semifluorinated alkane and one or more excipients. In some embodiments the liquid pharmaceutical composition comprises a mixture of two enantiomers of a pharmaceutically active compound or a pharmaceutically acceptable salt thereof selected from any row of Table 1, wherein the ratio of the first enantiomer (e.g. featured in column A; 2a to 76a) relative to the second enantiomer (e.g. featured in column B; 2b to 76b) is at least 89:11, 90:10, 91:8, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 or at least 99:1, wherein the enantiomers are dissolved or suspended in a semifluorinated alkane; or are dissolved or suspended in a vehicle comprising a semifluorinated alkane and one or moreexcipients. Herein, the mixture of the two enantiomers consists of the first enantiomer (e.g.featured in column A; 2a to 76a) and the corresponding second enantiomer (e.g. featured incolumn B; 2b to 76b) in the same row of Table 1 (for example the mixture of two enantiomersconsist of first enantiomer 4a, (S)-amlodipine, and second enantiomer 4b, (R)-amlodipine).In some embodiments, the (first) enantiomer is selected from the list consisting of (S)- abediterol (2a), (R)-albuterol (levalbuterol) (3a), (S)-amlodipine (levamlodipine) (4a), levoamphetamine (5a), (S)-atomoxetine (6a), levobetaxolol ((S)-betaxolol) (7a), (R)- bicalutamide (8a), levobunolol (9a), (S)-bupivacaine (levbupivacaine) (10a), levocabastine (11a), (S)-carteolol (12a), levocetirizin (13a), dexchlorpheniramine (14a), (S)- chlorpheniramine (dexchlorpheniramine) (15a), (S)-citalopram (escitalopram) (16a), (S)- cromoglicic acid (17a), (S)-dipivefrine (18a), (-)-dobutamine (19a), (R)-doxylamine (20a), (S)-duloxetine (21a), (-)-erythro-mefloquin (22a), levoketoconazole (23a), dexfenfluramine (24a), (R)-fenoldopam (25a), (-)-gusperimus (deoxyspergualin) (26a), (R)-lansoprazole (dexlansoprazole) (27a), (S)-lenalidomide (28a), levoleucovorin (29a), linezolid (S-isomer) (30a), (R)-lipoic acid (31a), (R)-mebeverine (32a), dexmedetomidine (33a), levomethadone (34a), L-methamphetamine (levmetamfetamine) (35a), (S)-methotrexate (36a), D- methylphenidate (dexmethylphenidate) (37a), (S)-metipranolol (38a), L-milnacipran (levomilnacipran) (39a), (R)-modafinil) (armodafinil) (40a), (S)-naproxen (41a), levonorgestrel (42a), (S)-omeprazole (esomeprazole) (43a), L-ormeloxifene (levormeloxifene) (44a), levoprotiline (45a), (R)-oxybutynin (46a), dexpanthenol (47a), (S)- pheniramine malleate (48a), (S)-pindolol (49a), (R)-pioglitazone (50a), (R)-pralatrexate (51a), (S)-procyclidine (52a), levo-epinephrine (53a), ropivacaine (S-isomer) (54a), (-)- rotigotine (55a), (R)-ruxolitinib (56a), (R)-salbutamol (levosalbutamol) (57a), L-scopolamine (58a), (R)-tedizolid (59a), (R)-thalidomide (60a), (+)-tramadol (61a), (+)-tranylcypromine(62a), (-)-trihexylphenidyl (63a), (R)-tropicamide (64a), (S)-valsartan (65a), L-verapamil(66a), (S)-vigabatrin (67a), (S)-warfarin (68a), (S)-zopiclone (eszoplicone) (69a), (R)-STX478 (70a), (2R,5S)-ritlecitinib (71a), (3S,4R)-delgocitinib (72a), (3R,4R)-tofacitinib (73a), 4- [(1R)-1-Phenylethyl]-1,3-benzenediol (74a), (2S)-3-phenyl-2-(undec-10- enoylamino)propanoic acid (75a) and (S)-equol (76a). In some embodiments, the (second) enantiomer is selected from the list consisting of (R)-abediterol (2b), (S)-albuterol (3b), (R)-amlodipine (4b), dextroamphetamine (5b), (R)-atomoxetine (6b), (R)-betaxolol (7b), (S)-bicalutamide (8b), dextrobunolol (9b), (R)- bupivacaine (10b), dextrocabastine (11b), (R)-carteolol (12b), dextrocetirizin (13b), (-)- chlorpheniramine (14b), (R)-chlorpheniramine (15b), (R)-citalopram (16b), (R)-cromoglicic acid (17b), (R)-dipivefrine (18b), (+)-dobutamine (19b), (S)-doxylamine (20b), (R)- duloxetine (21b), (+)-erythro-mefloquin (22b), dextroketoconazole (23b), levofenfluramine (24b), (S)-fenoldopam (25b), (+)-gusperimus (26b), (S)-lansoprazole (27b), (R)-lenalidomide (28b), dexleucovorin (29b), (R)-linezolid (30b), (S)-lipoic acid (31b), (S)-mebeverine (32b), levomedetomidine (33b), dexmethadone (34b), D-methamphetamine (dextromethamphetamine) (35b), (R)-methotrexate (36b), L-methylphenidate (37b), (R)- metipranolol (38b), D-milnacipran (levomilnacipran) (39b), (S)-modafinil (40b), (R)- naproxen (41b), dexnorgestrel (42b), (R)-omeprazole (43b), D-ormeloxifene (44b), dextroprotiline (45b), (S)-oxybutynin (46b), levopanthenol (47b), (R)-pheniramine malleate (48b), (R)-pindolol (49b), (S)-pioglitazone (50b), (S)-pralatrexate (51b), (R)-procyclidine (52b), dextro-epinephrine (53b), (R)-ropivacaine (54b), (+)-rotigotine (55b), (S)-ruxolitinib (56b), (S)-salbutamol (57b), D-scopolamine (58b), (S)-tedizolid (59b), (S)-thalidomide (60b), (-)-tramadol (61b), (-)-tranylcypromine (62b), (+)-trihexylphenidyl (63b), (S)-tropicamide (64b), (R)-valsartan (65b), D-verapamil (66b), (R)-vigabatrin (67b), (R)-warfarin (68b), (R)- zopiclone (eszoplicone) (69b), (S)-STX478 (70b), (2S,5R)-ritlecitinib (71b), (3R,4S)- delgocitinib (72b), (3S,4S)-tofacitinib (73b), 4-[(1S)-1-Phenylethyl]-1,3-benzenediol (74b), (2R)-3-phenyl-2-(undec-10-enoylamino)propanoic acid (75b) and (R)-equol (76b). Preferably, the pairs of the first and second enantiomers are respectively compounds 2a:2b, 3a:3b, 4a:4b, 5a:5b, 6a:6b, 7a:7b, 8a:8b, 9a:9b, 10a:10b, 11a:11b, 12a:12b, 13a:13b, 14a:14b, 15a:15b, 16a:16b, 17a:17b, 18a:18b, 19a:19b, 20a:20b, 21a:21b, 22a:22b, 23a:23b, 24a:24b, 25a:25b, 26a:26b, 27a:27b, 28a:28b, 29a:29b, 30a:30b, 31a:31b, 32a:32b, 33a:33b, 34a:34b, 35a:35b, 36a:36b, 37a:37b, 38a:38b, 39a:39b, 40a:40b, 41a:41b, 42a:42b, 43a:43b, 44a:44b, 45a:45b, 46a:46b, 47a:47b, 48a:48b, 49a:49b, 50a:50b, 51a:51b, 52a:52b, 53a:53b, 54a:54b, 55a:55b, 56a:56b, 57a:57b, 58a:58b, 59a:59b, 60a:60b, 61a:61b, 62a:62b, 63a:63b, 64a:64b, 65a:65b, 66a:66b, 67a:67b, 68a:68b, 69a:69b, 70a:70b, 71a:71b, 72a:72b, 73a:73b, 74a:74b,75a:75b, 76a:76b in Table 1.As mentioned, the compositions of the disclosure are compositions comprising asemifluorinated alkane. Semifluorinated alkanes are linear or branched alkanes where some of the hydrogen atoms are replaced by fluorine atoms. In one embodiment, the semifluorinated alkane (which may be abbreviated as SFAs) described and used according to the present disclosure comprises of one linear non-fluorinated hydrocarbon segment and of one linear perfluorinated hydrocarbon segment with the perfluorinated hydrocarbon segment attached to the non-fluorinated hydrocarbon segment. In a preferred embodiment, the semifluorinated alkanes used in the context of the present disclosure are preferably liquid semifluorinated alkanes. In an embodiment, the semifluorinated alkanes have the chemical formula F(CF2)n(CH2)mH, wherein n and m are integers defining the number of carbons in the perfluorinated hydrocarbon segment and non-fluorinated hydrocarbon segment respectively. In a further embodiment, the one or more semifluorinated alkanes featured in the compositions according to the present disclosure is a semifluorinated alkane of formula F(CF2)n(CH2)mH, wherein n is an integer selected from 4 to 6 and m is an integer selected from 2 to 10. In a further embodiment, the one or more semifluorinated alkanes is a semifluorinated alkane of formula F(CF2)n(CH2)mH, wherein n is an integer selected from 4 to 6 and m is an integer selected from 4 to 8. A nomenclature which is also frequently used for linear semifluorinated alkanes designates a perfluorinated hydrocarbon segment as RF and a non-fluorinated segment as RH, i.e. RFRH. Alternatively, the compounds may be referred to as FnHm, wherein F means a perfluorinated hydrocarbon segment, H means a non-fluorinated segment, and n and m define the number of carbon atoms of the respective segment. For example, F3H3 is used for perfluoropropylpropane, F(CF2)3(CH2)3H. Moreover, this type of nomenclature is usually used for compounds having linear i.e. unbranched segments. Therefore, unless otherwise indicated, it should be assumed that F3H3 means 1-perfluoropropylpropane, rather than its structural isomers e.g. branched isomers such as 2-perfluoropropylpropane, 1- perfluoroisopropylpropane or 2-perfluoroisopropylpropane.In one embodiment of the present disclosure, the composition or the vehicle of thecomposition may comprise of one or more semifluorinated alkanes selected from the group consisting of F4H4, F4H5, F4H6, F4H8, F6H2, F6H4, F6H6, F6H8, F6H10, or their structuralisomers, and mixtures thereof. The chemical formula of these semifluorinated alkanes may beexpressed, respectively as F(CF2)4(CH2)4H, F(CF2)4(CH2)5H, F(CF2)4(CH2)6H, F(CF2)4(CH2)8H, F(CF2)6(CH2)2H, F(CF2)6(CH2)4H, F(CF2)6(CH2)6H, F(CF2)6(CH2)8H and F(CF2)6(CH2)10H. Inanother embodiment, the vehicle comprises a semifluorinated alkane selected from F4H5,F4H6, F6H4, F6H6, F6H10, or their structural isomers, or any mixture or combination ofthese semifluorinated alkanes. In yet another embodiment, the composition, or the vehiclecomprises a semifluorinated alkane selected from the group consisting of F4H5, F4H6, F6H4,F6H6, F6H10, their structural isomers, and any mixtures thereof. In yet a further embodiment, the semifluorinated alkane is F4H5 (1-perfluorobutyl-pentane),F6H8 (1-perfluorohexyl-octane), their structure isomers or any mixtures for thesesemifluorinated alkanes.1-perfluorobutyl-pentane, with the chemical formulaF(CF2)4(CH2)5H, is an inert, water-insoluble liquid, with a density of 1.284 g / cm3 at 25 °C andrefractive index of 1.3204 at 20 °C. Alternative nomenclature for this compound includes F4H5, wherein F denotes a linear perfluorinated alkane segment comprising 4 carbon atoms and wherein H denotes a linear and non-fluorinated alkane segment of 5 carbon atoms. Preferably, the 1-perfluorobutyl-pentane is substantially free of water. Optionally, the formulation may comprise more than one semifluorinated alkane. As understood herein, the term ‘a’ semifluorinated alkane does not exclude the plurality, unless context provides otherwise. In other words, the compositions or methods according to thepresent disclosure may, in some embodiments, relate to the use or feature of one or moresemifluorinated alkanes. It may be useful to combine semifluorinated alkanes, for example, in order to achieve a particular target property such as a certain density or viscosity. If a mixture of semifluorinated alkanes is used, it is preferred that the mixture comprises at least one of F4H5, F4H6, F6H4, F6H6, F6H10. In one embodiment, the composition, or the vehicle comprise at least two members selected from the group consisting of F4H5, F4H6, F6H4, F6H6, F6H10. In one embodiment, the composition, or the vehicle comprises a mixture of 1- perfluorobutyl-pentane and 2-perfluorobutyl-pentane, optionally wherein the 2- perfluorobutyl-pentane is present in the vehicle an amount of up to 2 % (w / w), or up to 1 %(w / w), or up to 0.5 % (w / w) or up to 0.2 % (w / w); or in an amount of 0.1 % to 2% (w / w), or0.01% to 1 % (w / w) or 0.5% to 5 % (w / w) in respect total weight of the mixture ofsemifluorinated alkane. In yet a further embodiment, the vehicle of a composition according to the present disclosure comprises a mixture of 1-perfluorohexyl-octane and 2- perfluorohexyl-octane, optionally wherein the 2-perfluorohexyl-octane is present in an amount of up to 2 % (w / w), or up to 1 % (w / w), or up to 0.5 % (w / w), or in an amount of 0.1% to 2% (w / w), or 0.01% to 1 % (w / w) or 0.5% to 5 % (w / w) in respect total weight of themixture of semifluorinated alkane.In another embodiment, the vehicle of a composition according to the present disclosureessentially consists only of one or more semifluorinated alkanes as described herein, with nofurther excipients such as a cosolvent (e.g. ethanol) present. For example, in one embodiment, the vehicle consists only of a semifluorinated alkane selected from the groupconsisting of F4H5, F4H6, F6H4, F6H6, F6H10, or their structural isomers and anycombination or mixtures of these semifluorinated alkanes. Or in other words, the vehicle essentially consists of 100 % (w / w) of a semifluorinated alkane, or a mixture of semifluorinated alkane such as defined above. As used herein, the term “consists” and related terms “consisting” or “consist” is to be understood as meaning that no other features, other than those prefaced by the term are present. In the context of compositions, if any other constituent or component is present in the composition other than those prefaced by such term, then it is present only in trace or residual amounts such as to confer no technical advantage or relevance in respect of the object of the disclosure, such as may be further understood by the term ‘essentially” or “substantially” used in conjunction with these terms (e.g. ‘essentially consisting of”). In contrast, the term ‘comprising” or related terms “comprises” or “comprise” in the context of compositions, is to be understood as meaning that other features, other than those prefaced by the term may be present in the composition. As understood herein, the vehicle of a composition according to the present disclosure comprises at least one semifluorinated alkane. Said vehicle may optionally further compriseone or more excipients, as such as further described herein below. In one embodiment, thevehicle comprises more than one semifluorinated alkane. In another embodiment, the vehicleconsists of one or more semifluorinated alkanes and optionally one or more pharmaceuticallyacceptable excipients, preferably excipients which are miscible, or soluble in the semifluorinated alkane or semifluorinated alkane mixture. In one embodiment, the amount ofsemifluorinated alkane or mixture of semifluorinated alkanes in the composition is in anamount of at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.8% (w / w) with respect tothe total weight of the composition. In other embodiments according to the present disclosure, the pharmaceutical composition comprises from about 95 to about 99% (w / w), more preferably from about 98 to about 99%(w / w), even more preferably from about 98 to about 99.9% (w / w) of a semifluorinatedalkane as based on the total weight of the composition. In an embodiment, thepharmaceutical composition comprises at least about 90%, 95%, 96%, 97%, 98%, 99% or atleast 99.5% (w / w) of 1-perfluorobutyl-pentane (F4H5), and also optionally 2-perfluorobutyl-pentane, based on the total weight of the pharmaceutical composition. In a further embodiment, the pharmaceutical composition comprises at least about 90%, 95%, 96%, 97%, 98%, or at least 99% (w / w) of 1-perfluorobutyl-pentane (F4H5), and up to about 0.2%, 0.3%, 0.4%, 0.5% or up to about 1% (w / w) of 2-perfluorobutyl-pentane, based on the total weight of the pharmaceutical composition.In another embodiment, the pharmaceutical composition comprises at least about 90%, 95%,96%, 97%, 98%, 99% or at least 99.5% (w / w) of 1-perfluorohexyl-octane (F6H8), andoptionally 2-perfluorohexyl-octane, based on the total weight of the pharmaceutical composition. In a further embodiment, the pharmaceutical composition comprises at least about 90%, 95%, 96%, 97%, 98%, or at least 99% (w / w) of 1-perfluorohexyl-octane (F6H8),and up to about 0.2% , 0.3%, 0.4%, 0.5% (w / w) or up to about 1 % (w / w) of 2-perfluorohexyl-octane, based on the total weight of the pharmaceutical composition. In one embodiment, the pharmaceutical composition of the present disclosure is a solution. The term a “clear” solution, as understood herein, refers to a liquid solution in which all solutes are fully dissolvable or dissolved under room temperature conditions i.e. between 15 and 25 °C. The clear solution does not comprise of any particulate or solid phase components and preferably has a refractive index approximate to that of water (i.e.1.333) at room temperature.In one embodiment, the composition according to the present disclosure is in the form of asolution, or alternatively a suspension. The term “solution” or “clear solution” as such, as understood herein, refers to a liquid solution in which all solutes are fully dissolvable or dissolved under room temperature conditions i.e. between 15 and 25 °C. The resulting solution does not comprise of any particulate or solid phase components. In one embodiment, the pharmaceutical composition according to the present disclosure comprises anenantiomer of a compound e.g. selected from the Table 1 (any one of 2a to 76a, or any one of2b to 76b), dissolved in a vehicle comprising one or more of any one or combination ofsemifluorinated alkane as defined herein, and optionally one or more excipients as definedherein, wherein the composition is in the form of a clear solution.A ‘suspension’ on the other hand may be defined as a type of a dispersion, a dispersion being a system having at least one continuous (or coherent) phase and at least one discontinuous (or inner) phase which is dispersed in the continuous phase. In a suspension, the dispersedphase is in the solid state. For example, and in the context of the present disclosure, a particle(i.e. in a solid state) comprising, or consisting of an isomerizable pharmaceutically activecompound or a pharmaceutically acceptable salt thereof e.g. as provided for in Table 1 (e.g.any one of 2a to 76a, or any one of 2b to 76b) may be suspended in the liquid vehicle of thecomposition. The suspensions useful for practising the present disclosure are preferablyliquid suspensions, wherein the continuous phase is a liquid, and are formulated so as to be suitable administration as a medicament. In another embodiment, the pharmaceutical composition according to the present disclosureconsists of an enantiomer of a pharmaceutically active compound or a pharmaceuticallyacceptable salt thereof, wherein the enantiomer is present in the composition in an enantiomeric excess of at least 78%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,90%, 91%, 93%, 96%, 97%, 98% or 99%, and wherein the enantiomer is suspended in one ormore of any one or combination of semifluorinated alkane as defined herein. In anotherembodiment, the pharmaceutical composition according to the present disclosure consist of(a mixture of two) enantiomers of a compound or a pharmaceutically acceptable salt thereofselected from any row of Table 1, wherein the ratio of the first enantiomer (featured in column A; 2a to 76a) relative to the second enantiomer (featured in column B; 2b to 76b) is at least 89:11, 90:10, 91:8, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 or at least 99:1, wherein the (mixture of two) enantiomers are suspended in one or more of any one or combination of semifluorinated alkane as defined herein. Optionally, the compositions according to the present disclosure may comprise of a vehiclecomprising, in addition to the at least one semifluorinated alkane, one or more excipients. Inone embodiment, the vehicle of the composition consists of at least one semifluorinated alkane and one or more excipients. The term “excipients” as used herein refers to any pharmaceutically acceptable, natural, synthetic or semi-synthetic substance, compound or component that may be included in the vehicle and thus the composition as described herein, for example to enhance or otherwise modify the physical or chemical constitution or stability of the composition. Pharmaceutically acceptable means that the excipient is safe, non-toxic, biocompatible and physiologically tolerated e.g. for human pharmaceutical use; preferably,the excipient is suitable and safe for topical administration to a human eye or its associatedophthalmic tissues. Examples of excipients which may be featured in the compositions according to the present disclosure include, but are not limited to, co-solvents, antioxidants, a preservative, lipids, oily excipients, surfactants, lubricant or combinations thereof. In one embodiment, the excipient is a liquid which is miscible with a semifluorinated alkane, and in case of more than oneexcipient being featured in the vehicle, also miscible with any of the other excipients featuredin the vehicle of the composition. The excipient in one embodiment may function as a co-solvent, i.e. is a compound which is suitable for enhancing solubility or solubilizing the activecompound, and / or another excipient featured in the composition. The co-solvent ispreferably a liquid that is fully miscible with the semifluorinated alkane, i.e. it mixes with the semifluorinated alkane to form a coherent and single phase. In another embodiment, the excipient may be dissolved in the semifluorinated alkane.In some embodiments, the excipient is a co-solvent. The co-solvent may be an alcohol, such asan alkyl alcohol. In one embodiment, the alcohol is selected from ethanol, 1-propanol, isopropanol, and phenylethyl alcohol; or more preferably from ethanol and phenylethylalcohol. Alternatively, the vehicle of the composition may comprise, or consists in addition toa semifluorinated alkane (or mixture of semifluorinated alkanes) as defined herein, at leastone excipient, with the proviso that the excipient is not an alcohol, and / or is not medium chain triglycerides (MCT) and / or is not light liquid paraffin.In some embodiments, the excipient featured in the vehicle is an oily excipient. Examples ofoily excipients are triglycerides, mineral oil, and liquid paraffin. In one embodiment, inaddition to a semifluorinated alkane the vehicle comprises an oily excipient is selected from medium chain triglycerides (MCT) and light liquid paraffin. In some embodiments, the vehicle of the composition comprises, or consists of at least onesemifluorinated alkane and a combination of any one of a co-solvent or oily excipient asdescribed herein above. In some embodiments, the one or more excipients is present in the composition, optionallyindependently, in an amount of up to 0.1 wt %, 0.5 wt%, 0.75 wt%, 1.0 wt%, 1.25 wt%, 1.4wt%, 1.5 wt%, 1.8 wt%, 2.0 wt%, 3.0 wt%, 4.0 wt% or up to 5.0 wt% (w / w), or preferably upto 1 wt% or up to 1.4 wt%, based on the total weight of the composition. In otherembodiments, the composition comprises one or more excipients, optionally independently,in an amount of between 0.1 to 5.0 wt%, or between 0.1 to 2.0 wt% or between 0.01 to 1.4wt%, based on the total weight of the composition. In other embodiments, the one or more excipients is present in the composition, optionally independently, in an amount of up to 0.1 % (v / v), 0.5 % (v / v), 0.75 % (v / v), 1.0 % (v / v), 1.25 % (v / v), 1.4 % (v / v), 1.5 % (v / v), 1.8 % (v / v), 2.0 % (v / v), 3.0 % (v / v), 4.0 % (v / v) or up to 5.0 % (v / v) (w / w), or preferably up to 1 % (v / v) or up to 1.4 % (v / v), based on the total volume of the composition. In other embodiments, the composition comprises one or more excipients, optionally independently, in an amount of between 0.1 to 5.0 % (v / v), or between 0.1 to 2.0 % (v / v) or between 0.01 to 1.4 % (v / v), based on the total volume of the composition. In other embodiments, the composition is essentially free of a) water; or b) a preservative. As used herein, the term “up to about” or “up to” used in context of a parameter, such as inrelation to the concentration or amount of an isomerizable active compound, e.g. any one ofthe enantiomer compounds as disclosed herein, e.g. as selected from Table 1 (any one ofcompounds 2a to 76a, 2b to 76b), or presently in relation to the amount of the one or moreexcipient in the composition, refers to any value of the parameter greater than zero and up to, and inclusive of, the defined parameter, taking into account any degree of variability usually observed in measuring or determining this parameter, using the standard techniques and equipment known in the relevant field.As understood herein, the term “% (w / v)” unless otherwise indicated refers to the amount ofa component of a composition as a weight percentage in relation to the total volume of the composition (with “w” denoting weight and “v” denoting volume). For example, a 0.1 % (w / v) would correspond to 1.0 mg of a component in 1 mL of the composition. The term “% (w / w)” or alternatively, “wt %” as used herein and unless otherwise indicated refers to the amount of a component of a composition as a weight percentage in relation to the total weight of the composition with ‘w’ denoting weight. The term % (v / v), or volume percent asused herein, and unless otherwise indicated, refers to the volume of a component of acomposition in relation to the total volume of the composition. As understood herein, the term ‘essentially free’, or alternatively ‘substantially free’ or ‘component-free’ in reference to a composition constituent or component refers to the presence of said component in no more than trace amounts and that if present in trace amounts the component does not provide any technical contribution or material advantage to the composition. The compositions described herein are, in one embodiment, essentially freeof water. In another embodiment, the composition described herein may be essentially free ofa preservative, such as an anti-microbial preservative. The term ‘about’ as used herein and in reference or connection to a parameter, for examplesuch as the amount or concentration of a compound dissolved or suspended in thecomposition includes the precise value as defined, as well as any value falling within the degree of variability usually observed in measuring or determining these parameters using the standard techniques and equipment known in the art and field.Also as understood herein, a pharmaceutically acceptable salt is a pharmaceuticallyacceptable salt is a salt of a compound such as provided herein, which retains its biologicalproperties, and which is non-toxic and is compatible for pharmaceutical use. Salts, forexample, may result from an addition of an acid, such as an organic acid or a mineral acid, such as sulfuric acid, or hydrochloric acid. The compositions of the present disclosure are compositions containing higher enantiomeric ratio, or predominantly one enantiomer of an active pharmaceutically active compound, such as a compound as defined in herein above. These are formulated in a semifluorinated alkaneand may remain stable also under long term storage conditions, with minimal or reduceddegradation or loss of the enantiopurity or stereochemical purity of the compound in the composition. Pharmaceutically active compounds may be provided as racemate form where only one of the compounds may have the desirable pharmacological or therapeutic effect, as maintaining stereochemical purity of e.g. the desired enantiomer may be difficult due to stability issues and / or propensity of the compound under storage conditions towards gradual racemization. From a treatment efficacy point of view a loss or diminished accuracyin dosing is not desirable. Moreover, the absence, or else a much lower amount of a non-therapeutically relevant enantiomer in a medicament may be advantageous in that this reduces or avoids unnecessary exposure of a subject to this compound which despite its non-therapeutic effect (or not yet known adverse effect), a subject’s physiology could still be(adversely) reactive to.A composition containing higher enantiomeric ratio, or predominantly of the activeenantiomer selected from the list consisting of (S)-abediterol (2a), (R)-albuterol (levalbuterol) (3a), (S)-amlodipine (levamlodipine) (4a), levoamphetamine (5a), (S)- atomoxetine (6a), levobetaxolol ((S)-betaxolol) (7a), (R)-bicalutamide (8a), levobunolol (9a), (S)-bupivacaine (levbupivacaine) (10a), levocabastine (11a), (S)-carteolol (12a), levocetirizin (13a), dexchlorpheniramine (14a), (S)-chlorpheniramine (dexchlorpheniramine) (15a), (S)- citalopram (escitalopram) (16a), (S)-cromoglicic acid (17a), (S)-dipivefrine (18a), (-)- dobutamine (19a), (R)-doxylamine (20a), (S)-duloxetine (21a), (-)-erythro-mefloquin (22a), levoketoconazole (23a), dexfenfluramine (24a), (R)-fenoldopam (25a), (-)-gusperimus (deoxyspergualin) (26a), (R)-lansoprazole (dexlansoprazole) (27a), (S)-lenalidomide (28a), levoleucovorin (29a), linezolid (S-isomer) (30a), (R)-lipoic acid (31a), (R)-mebeverine (32a), dexmedetomidine (33a), levomethadone (34a), L-methamphetamine (levmetamfetamine) (35a), (S)-methotrexate (36a), D-methylphenidate (dexmethylphenidate) (37a), (S)- metipranolol (38a), L-milnacipran (levomilnacipran) (39a), (R)-modafinil) (armodafinil) (40a), (S)-naproxen (41a), levonorgestrel (42a), (S)-omeprazole (esomeprazole) (43a), L- ormeloxifene (levormeloxifene) (44a), levoprotiline (45a), (R)-oxybutynin (46a), dexpanthenol (47a), (S)-pheniramine malleate (48a), (S)-pindolol (49a), (R)-pioglitazone (50a), (R)-pralatrexate (51a), (S)-procyclidine (52a), levo-epinephrine (53a), ropivacaine (S- isomer) (54a), (-)-rotigotine (55a), (R)-ruxolitinib (56a), (R)-salbutamol (levosalbutamol) (57a), L-scopolamine (58a), (R)-tedizolid (59a), (R)-thalidomide (60a), (+)-tramadol (61a), (+)-tranylcypromine (62a), (-)-trihexylphenidyl (63a), (R)-tropicamide (64a), (S)-valsartan (65a), L-verapamil (66a), (S)-vigabatrin (67a), (S)-warfarin (68a), (S)-zopiclone (eszoplicone) (69a), (R)-STX478 (70a), (2R,5S)-ritlecitinib (71a), (3S,4R)-delgocitinib (72a), (3R,4R)-tofacitinib (73a), 4-[(1R)-1-Phenylethyl]-1,3-benzenediol (74a), (2S)-3-phenyl-2- (undec-10-enoylamino)propanoic acid (75a) and (S)-equol (76a), or their enantiomer, maybe formulated in a semifluorinated alkane and remain stable also under long term storageconditions. The stability may be defined as minimal to no degradation of the compound, suchas often observed in aqueous formulations of this compound, and also in respect to racemization or reduction in enantiomeric ratio in respect to the formation of the respectiveenantiomer over time, providing for an improved shelf-stable composition.The enantiomeric ratio, or enantiomeric excess (ee) of a compound or in general, thestereochemical purity of a compound, or specifically an enantiomer as described herein inTable 1 (any one of Compounds 2a to 76a, 2b to 76b), and the quantification of the amount,relative or otherwise, of the active compound, their isomers or degradation products featuredin a composition according to the present disclosure may be determined via a number of methods in the art, for example, but not limited to chromatography methods such as HPLC,capillary electrophoresis, LC-MS or gas chromatography, and / or spectroscopic methods suchas circular dichroism or NMR. In one embodiment, the enantiomeric ratio is determined by HPLC, preferably from quantification of the peak areas of the respective compounds. In some embodiments, the liquid pharmaceutical composition according to the presentdisclosure comprises the enantiomer (or the mixture of two enantiomers) of apharmaceutically active compound or a pharmaceutically acceptable salt thereof, preferablyselected from an enantiomer as described herein in Table 1 (2a to 76a, 2b to 76b), whereinthe concentration of the compound in the liquid pharmaceutical composition is 0.01 to 5%(w / v), 0.05 to 5% (w / v), 0.05 to 2% (w / v), 0.1 to 2% (w / v), 0.1 to 1% (w / v), or wherein the concentration of the compound in the liquid pharmaceutical composition is 0.5 to 1.0%(w / v). Preferably, the liquid pharmaceutical composition comprises the enantiomer (or themixture of two enantiomers) of a pharmaceutically active compound or a pharmaceuticallyacceptable salt thereof, preferably selected from an enantiomer or enantiomer pair asdescribed herein in Table 1 (2a to 76a, 2b to 76b), wherein the concentration of thecompound in the liquid pharmaceutical composition is at least 0.01% (w / v), 0.05% (w / v),0.1% (w / v), 0.5% (w / v), 1% (w / v), 2% (w / v) or at least 5% (w / v). In some embodiments,the liquid pharmaceutical composition comprises the enantiomer (or the mixture of twoenantiomers) of a pharmaceutically active compound or a pharmaceutically acceptable saltthereof, preferably selected from an enantiomer or enantiomer pair as described herein inTable 1 (2a to 76a, 2b to 76b) , wherein the concentration of the compound in the liquidpharmaceutical composition is below 10% (w / v), 5% (w / v), 3% (w / v), 2 (w / v), 1% (w / v), 0.5% (w / v), 0.1% (w / v), 0.05% (w / v) or below 0.01% (w / v).In other embodiments, the amount of a compound in a composition according to the presentdisclosure, i.e. an enantiomer as described in Table 1 (2a to 76a, 2b to 76b) or any of the listsas provided in the current disclosure after storage at 0 to 60°C, e.g. storage at 25 °C for at least 1, 2, 3, 4, 5, 6, 9, or 12 months is at least 90%, or at least 95% or at least 99% relative tothe initial amount of the enantiomer as determined for the composition, e.g. by HPLC.In some embodiments, the concentration or amount of an enantiomer in a liquid compositionaccording to the present disclosure, e.g. as described in Table 1 (2a to 76a, 2b to 76b) or any of the lists as provided in the current disclosure, after storage at 0 to 60°C, e.g. storage at 25°C for at least 1, 2, 3, 4, 5, 6, 9 or at least 12 months is in the range of 80 to 120%, 85 to 115%, 90 to 110%, or 95 to 105 % of the initial concentration of the enantiomer in the composition e.g. asdetermined by HPLC. In other related embodiments, the concentration of enantiomer afterstorage of the composition at 25°C for at least 3 months is in the range of about 90-110%; or is not less than 90% (e.g.91, 92 ,93 ,94, 95 ,96, 97, 98, 99%); or is not higher than 100% (e.g. not higher than 101, 102, 103, 104, 105, 106, 107, 108, or 109%), e.g. as determined by HPLC, preferably by quantification of the peak areas of the respective compounds. Where the percentage determined is greater than 100%, it is to be understood that the measurement doesnot relate to an increase in amount of the enantiomer, but e.g. rather translates to a loss ofvehicle over time during storage. In further related embodiments, the amount of the enantiomer or preferably equal or greater than 80%, 85%, or 90%, or 95% of the initial concentration of the enantiomer in the composition, or equal to or less than 120%, 115%,110%, 105 % or 100% of the initial concentration of enantiomer in the composition.In some embodiments, the enantiomeric ratio of a first enantiomer (e.g.2a to 76a) to thesecond enantiomer (e.g.2b to 76b) (ref. Table 1 above) in a liquid pharmaceuticalcomposition according to the present disclosure after storage at 25 °C for at least 1, 2, 3, 4, 5, 6, 9, or at least 12 months has not decreased by more than 0.5%, 1.0%, 2.0%, 2.5%, 5%, 7.5%, 10%, 15%, 20%, or 25%. For example, in a composition comprising a first enantiomer dissolved in a semifluorinated alkane and optional excipient(s), wherein the initial enantiomeric ratio to the second enantiomer is 90:10, i.e.9, prior to storage or aging, a decrease of about 1% would amount in a decrease of the enantiomeric ratio to 8.91%, or about 89.91 : 10.09. In another aspect, the disclosure relates to a method for the preparation of a liquid pharmaceutical composition as defined according to any one of the embodiments describedherein; said method comprising a step of dissolving or suspending an enantiomericcompound or enantiomers (or mixture of two enantiomers) as described herein above, e.g. inTable 1 (2a to 76a, 2b to 76b) in semifluorinated alkane or a non-aqueous vehicle comprising,or consisting of a semifluorinated alkane, and optionally one or more excipients, wherein the semifluorinated alkane is selected from the group consisting of F4H5, F4H6, F6H4, F6H6, F6H8, F6H10, or their structural isomers and any combination thereof. In yet another aspect, the disclosure relates to a method for stabilizing an isomerizable pharmaceutical compound or a pharmaceutically acceptable salt thereof in a composition, or for preventing the isomerization of an isomerizable pharmaceutical compound or a pharmaceutically acceptable salt thereof in a composition, wherein the method comprises a step of dissolving or suspending the compound in a semifluorinated alkane, or a vehicle consisting of a semifluorinated alkane and one or more excipients. The isomerizable pharmaceutical may be a compound as defined herein above. In some embodiments, the isomerizable compound has a purity of at least 90% or at least 92% or at least 95% or at least 97% (e.g. by HPLC). Preferably, the isomerizable pharmaceutical compound comprises at least one chiral stereocenter. The chiral stereocenter may besusceptible to racemization, inversion or epimerization; preferably the chiral stereocentermay be susceptible to racemization, inversion or epimerization under basic or acidicconditions. In some embodiments of this method, after storage of the composition for a period of at least 1, 2, 3, 4, 5, 6, 9 or 12 months at 0 to 60 °C (e.g. at 25 °C), the amount of the other isomer (e.g. undesired enantiomer or epimer) of the isomerizable pharmaceutical compound in the composition is independently less than 10%, less than 5%, less than 4% , less than 3%, less than 2%, less than 1% or less than 0.5% (e.g. by HPLC).In a related aspect, the disclosure provides a method for stabilizing, preventing, or reducingthe loss of stereochemical or enantiomeric purity of an enantiomer of a pharmaceutically active compound, or a pharmaceutically acceptable salt thereof in a liquid composition, wherein the method comprises a step of dissolving or suspending the enantiomer in a semifluorinated alkane, or in a vehicle comprising a semifluorinated alkane and one or more excipients. In some embodiments, the purity of the enantiomer in the composition is at least90% or at least 95% or at least 97% (e.g. by HPLC) when it is formulated in thesemifluorinated alkane or the vehicle.In related embodiments, provided is a method of stabilizing, preventing, or reducing the lossof enantiomeric excess of an enantiomer of a pharmaceutically active compound, or a pharmaceutically acceptable salt thereof in a liquid composition, wherein the methodcomprises a step of dissolving or suspending the enantiomer (provided at defined opticalpurity) in a semifluorinated alkane, or in a vehicle comprising a semifluorinated alkane andone or more excipients. In some embodiments, the enantiomeric excess of the enantiomer in the liquid composition is at least 78%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%,89%, 90%, 91%, 93%, 96%, 97%, 98% or 99% (e.g. by HPLC) when it is formulated in thesemifluorinated alkane, or the vehicle comprising (or consisting) the semifluorinated alkane and one or more excipients as defined herein. The method thus provides for a way of maintaining, or preventing significant changes with respect to the enantiopurity of the compound. In related embodiments, provided is a method of stabilizing, preventing, or loss ofenantiomeric ratio with respect to enantiomers (an enantiomer pair or mixture of twoenantiomers) of a pharmaceutically active compound or a pharmaceutically acceptable salt thereof in a liquid composition, wherein the method comprises a step of dissolving or suspending the enantiomers (or mixture of two enantiomers) in a semifluorinated alkane, or in a vehicle comprising a semifluorinated alkane and one or more excipients, as described inthe present disclosure. In some embodiments, the ratio of the first enantiomer relative to thesecond enantiomer is at least 89:11, 90:10, 91:8, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 or atleast 99:1, e.g. when it is dissolved or suspended in the semifluorinated alkane. Preferably,the first enantiomer is selected from the compounds 2a to 76a, and the corresponding secondenantiomer is selected from compounds 2b to 76b of Table 1.Said methods may provide for the prevention of, or reduction in the rate of degradation (e.g.hydrolysis and / or dehydration) and / or provide for the prevention, or reduction of the rate ofisomerization e.g. racemization or epimerization of the enantiomer in the composition into adifferent stereoisomer, or its enantiomer. In some embodiments these methods, theenantiomer, or the first enantiomer comprises a chiral stereocenter on a carbon atom, wherein at least one of the substituents of the chiral stereocenter is i) a hydrogen moiety prone to deprotonation under basic conditions and / or ii) is an alcohol moiety prone to dehydration under acidic conditions; and / or is susceptible to racemization, isomerization orepimerization. In other embodiments, the enantiomer or first enantiomer is selected from thelist consisting of (S)-abediterol (2a), (R)-albuterol (levalbuterol) (3a), (S)-amlodipine (levamlodipine) (4a), levoamphetamine (5a), (S)-atomoxetine (6a), levobetaxolol ((S)- betaxolol) (7a), (R)-bicalutamide (8a), levobunolol (9a), (S)-bupivacaine (levbupivacaine) (10a), levocabastine (11a), (S)-carteolol (12a), levocetirizin (13a), dexchlorpheniramine (14a), (S)-chlorpheniramine (dexchlorpheniramine) (15a), (S)-citalopram (escitalopram) (16a), (S)-cromoglicic acid (17a), (S)-dipivefrine (18a), (-)-dobutamine (19a), (R)- doxylamine (20a), (S)-duloxetine (21a), (-)-erythro-mefloquin (22a), levoketoconazole (23a), dexfenfluramine (24a), (R)-fenoldopam (25a), (-)-gusperimus (deoxyspergualin) (26a), (R)- lansoprazole (dexlansoprazole) (27a), (S)-lenalidomide (28a), levoleucovorin (29a), linezolid (S-isomer) (30a), (R)-lipoic acid (31a), (R)-mebeverine (32a), dexmedetomidine (33a), levomethadone (34a), L-methamphetamine (levmetamfetamine) (35a), (S)-methotrexate (36a), D-methylphenidate (dexmethylphenidate) (37a), (S)-metipranolol (38a), L- milnacipran (levomilnacipran) (39a), (R)-modafinil) (armodafinil) (40a), (S)-naproxen (41a), levonorgestrel (42a), (S)-omeprazole (esomeprazole) (43a), L-ormeloxifene (levormeloxifene) (44a), levoprotiline (45a), (R)-oxybutynin (46a), dexpanthenol (47a), (S)- pheniramine malleate (48a), (S)-pindolol (49a), (R)-pioglitazone (50a), (R)-pralatrexate (51a), (S)-procyclidine (52a), levo-epinephrine (53a), ropivacaine (S-isomer) (54a), (-)- rotigotine (55a), (R)-ruxolitinib (56a), (R)-salbutamol (levosalbutamol) (57a), L-scopolamine (58a), (R)-tedizolid (59a), (R)-thalidomide (60a), (+)-tramadol (61a), (+)-tranylcypromine (62a), (-)-trihexylphenidyl (63a), (R)-tropicamide (64a), (S)-valsartan (65a), L-verapamil (66a), (S)-vigabatrin (67a), (S)-warfarin (68a), (S)-zopiclone (eszoplicone) (69a), (R)-STX478 (70a), (2R,5S)-ritlecitinib (71a), (3S,4R)-delgocitinib (72a), (3R,4R)-tofacitinib (73a), 4- [(1R)-1-Phenylethyl]-1,3-benzenediol (74a), (2S)-3-phenyl-2-(undec-10- enoylamino)propanoic acid (75a) and (S)-equol (76a), or from Table 1 Column A, or fromTable 1 Column B. Moreover, the compositions of such methods may be in accordance withany one or combination of the compositions as described herein e.g in respect to the semifluorinated alkane, excipients, etc. In some embodiments of these methods, provided for is the storage of the composition for a period of at least 1, 2, 3, 4, 5, 6, 9 or 12 months at 0 to 60 °C (e.g. at 25 °C), wherein over said period,i) the concentration of the enantiomer(s) in the composition remains essentially thesame, or has not changed or decreased by more than 10%, more than 5%, more than 4% , more than 3%, more than 2%, more than 1% or more than 0.5% (e.g. as determined by HPLC) with respect to its initial concentration in the composition prior to storage; and / orii) the enantiomeric excess of the enantiomer is essentially the same, or has not changedor decreased by more than 10%, more than 5%, more than 4% , more than 3%, more than 2%, more than 1% or more than 0.5% with respect to the initially determined value prior tostorage; and / oriii) the enantiomeric ratio of the first enantiomer with respect to the second enantiomeris the same, or within 10% or 5% or 4%, or 3% or 1% of the enantiomeric ratio prior to storage.In another aspect, the present disclosure relates to a pharmaceutical composition comprisinga pharmaceutically active compound selected from the list consisting of the compounds 2a to76a featured in Column A, or compounds 2b to 76b featured in Column B of Table 1 asreferenced above or a pharmaceutically acceptable salt thereof, wherein thepharmaceutically active compound is (R)-ruxolitinib, and wherein (R)-ruxolitinib is dissolvedor suspended in a vehicle comprising a semifluorinated alkane and optionally one or more excipients. The semifluorinated alkane is in one embodiment, F4H5, F4H6, F6H4, F6H6, F6H8, F6H10, the structural isomers of these semifluorinated alkanes or any combination ormixtures of these compounds. Preferably, said compositions are liquid compositions.In a related aspect, the present disclosure relates to a liquid pharmaceutical compositioncomprising an enantiomer of a pharmaceutically active compound or a pharmaceutically acceptable salt thereof, wherein the enantiomer is present in the composition in an enantiomeric excess of at least 78%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 93%, 96%, 97%, 98% or 99%, and wherein the enantiomer is dissolved or suspended in a semifluorinated alkane, or dissolved or suspended in a vehicle comprising of asemifluorinated alkane and one or more excipients, wherein the enantiomer is (R)-ruxolitinib(56a in Table 1).In yet another and related aspect, the present disclosure relates to a liquid pharmaceutical composition comprising enantiomers of a pharmaceutically active compound or a pharmaceutically acceptable salt thereof, wherein the ratio of the first enantiomer relative to the second enantiomer is at least 89:11, 90:10, 91:8, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 or at least 99:1, wherein the enantiomers are dissolved or suspended in a semifluorinated alkane; or are dissolved or suspended in a vehicle comprising a semifluorinated alkane and one or more excipients, wherein the first enantiomer is (R)-ruxolitinib (56a, Table 1) and wherein the second enantiomer is (S)-ruxolitinib (56b, Table1).With respect to these aspects, in some embodiments the semifluorinated alkane is selectedfrom the group consisting of F4H5, F4H6, F6H4, F6H6, F6H8, F6H10, their structural isomersand any combinations thereof. In some embodiments, the semifluorinated alkane is selected from the group consisting of F4H5 (1-perfluorobutyl-pentane), F6H8 (1-perfluorohexyl-octane), their structural isomers and any combinations thereof. In other embodiments,semifluorinated alkane is 1-perfluorobutyl-pentane, and optionally 2-perfluorobutyl-pentane, wherein the 2-perfluorobutyl-pentane is present in an amount of up to 2 % (w / w), or up to 1 % (w / w), or up to 0.5 % (w / w) or up to 0.2 % (w / w in respect of the total weight of the mixture of semifluorinated alkanes. In other embodiments, the liquid pharmaceutical composition comprising (R)-ruxolitinib dissolved or suspended in a vehicle comprising of a semifluorinated alkane and one or more excipients, the semifluorinated alkane is 1-perfluorohexyl-octane, and optionally 2-perfluorohexyl-octane, wherein the 2-perfluorohexyl-octane is present in an amount of up to2 % (w / w), or up to 1 % (w / w), or up to 0.5 % (w / w) in respect of the total weight of the mixture of semifluorinated alkanes. Alternatively, in some embodiments, the vehicle consists of the semifluorinated alkane, or a mixture of semifluorinated alkanes. With respect to the amount of semifluorinated alkane in the composition, in some embodiments, the semifluorinated alkane or semifluorinated alkanes is / are present in an amount of at least 90%, 95%, 96%, 97%, 98%, 99% (w / w), based on the total weight of the composition. In some embodiments of the liquid pharmaceutical composition comprising (R)-ruxolitinibabove or a pharmaceutically acceptable salt thereof, the semifluorinated alkane is 1-perfluorobutyl-pentane (F4H5) and is present in an amount of at least 90%, 95%, 96%, 97%,98%, 99% (w / w), based on the total weight of the composition. In some embodiments, thesemifluorinated alkane is 1-perfluorobutyl-pentane (F4H5), and optionally also 2- perfluorobutyl-pentane and is / are present in an amount of at least 90%, 95%, 96%, 97%, 98%, 99% (w / w), based on the total weight of the composition.In other embodiments, the semifluorinated alkane is 1-perfluorohexyl-octane (F6H8) and ispresent in an amount of at least 90%, 95%, 96%, 97%, 98%, 99% (w / w), based on the totalweight of the composition. In some embodiments, the semifluorinated alkane is 1-perfluorohexyl-octane (F6H8), and optionally also 2-perfluorohexyl-octane and is / are present at least in an amount about 90%, 95% 96%, 97%, 98%, 99% or at least 99.5% (w / w), based on the total weight of the pharmaceutical composition. In some embodiments of the liquid pharmaceutical composition as defined herein comprising(R)-ruxolitinib or a pharmaceutically acceptable salt thereof, the vehicle comprises the semifluorinated alkane is a 1-perfluorohexyl-octane (F6H8), and optionally also 2- perfluorohexyl-octane and is / are present in an amount of at least 90%, 95%, 96%, 97%, 98%, 99% (v / v), based on the total volume of the composition. In some embodiments, the vehicle comprises or consists of the semifluorinated alkane andone or more excipients, wherein the one or more excipients is selected from a co-solvent, anoily excipient, or any combination of a co-solvent or oily excipient, such as defined herein. Insome embodiments, said one or more excipient is a co-solvent, wherein the co-solvent is analcohol. In some embodiments, the alcohol is selected from ethanol, 1-propanol, isopropanol, and phenylethyl alcohol; or more preferably wherein the alcohol is selected from ethanol and phenylethyl alcohol. In some embodiments, the oily excipient is selected from triglycerides,mineral oil, and liquid paraffin. In some embodiments, the oily excipient is selected frommedium chain triglycerides (MCT) and light liquid paraffin. With respect to the amount of theone or more excipients in the composition, in some embodiments, the one or more excipientsis present in an amount of up to 0.1 %, 0.5 wt%, 0.75 wt%, 1.0 wt%, 1.25 wt%, 1.4 wt%, 1.5 wt%, 1.8 wt%, 2.0 wt%, 3.0 wt%, 4.0 wt% or up to 5.0 wt% (w / w), preferably up to 1 wt% or up to 1.4 wt%, based on the total weight of the composition. Alternatively, in some embodiments of the composition as defined herein comprising (R)- ruxolitinib or a pharmaceutically acceptable salt thereof, the vehicle consists of a semifluorinated alkane, and optionally a structural isomer thereof, and one or more excipients, wherein the one or more excipient is not an alcohol, and / or is not medium chaintriglycerides (MCT) and / or is not light liquid paraffin.In another aspect, the present disclosure relates to a method of stabilizing, preventing, orreducing the loss of enantiomeric excess of an enantiomer of a pharmaceutically active compound, or a pharmaceutically acceptable salt thereof in a liquid composition, wherein theenantiomer is (R)-ruxolitinib (56a in Table 1) and wherein the method comprises a step ofdissolving or suspending the enantiomer in a semifluorinated alkane, or in a vehiclecomprising a semifluorinated alkane and one or more excipients. In some embodiments theenantiomeric excess of the enantiomer (R)-ruxolitinib in the liquid composition is at least 78%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 93%, 96%, 97%,98% or 99% (e.g. by HPLC).In yet another aspect, the disclosure relates to a method of stabilizing, preventing, or reducing the loss of enantiomeric ratio with respect to enantiomers of a pharmaceutically active compound or a pharmaceutically acceptable salt thereof in a liquid composition, wherein the method comprises a step of dissolving or suspending a mixture of two enantiomers in a semifluorinated alkane, or in a vehicle comprising a semifluorinated alkane and one or more excipients, wherein the mixture of two enantiomers are (R)-ruxolitinib (56ain Table 1)and (S)-ruxolitinib (56b in Table 1). In some embodiments, the ratio of the firstenantiomer relative to the second enantiomer (ratio of (R)-ruxolitinib to (S)-ruxolitinib) is atleast 89:11, 90:10, 91:8, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 or at least 99:1 In yet a further and related aspect, the disclosure relates to a method of stabilizing, preventing, or reducing the loss stereochemical or enantiomeric purity of an enantiomer of a pharmaceutically active compound, or a pharmaceutically acceptable salt thereof in a liquidcomposition, wherein the enantiomer is (R)-ruxolitinib, and wherein the method comprises astep of dissolving or suspending the enantiomer in a semifluorinated alkane, or in a vehiclecomprising a semifluorinated alkane and one or more excipients. In some embodiments, theenantiomeric purity of the(R)-ruxolitinib in the composition is at least 90% or at least 95% orat least 97% (e.g. by HPLC). In some embodiments of said method, the concentration of theenantiomer is essentially the same, or has not changed or decreased after storage of thecomposition for a period of at least 1, 2, 3, 4, 5, 6, 9 or 12 months at 0 to 60 °C (e.g. at 25 °C), by more than 10%, more than 5%, more than 4%, more than 3%, more than 2%, more than 1% or more than 0.5% (e.g. as determined by HPLC) with respect to its initial concentrationin the composition prior to storage; and / or the enantiomeric excess of the enantiomer, or thefirst enantiomer is essentially the same, or has not changed or decreased by more than 10%, more than 5%, more than 4%, more than 3%, more than 2%, more than 1% or more than0.5% with respect to the initially determined value prior to storage; and / or the enantiomericratio of the first enantiomer with respect to the second enantiomer is the same, or has not decreased 0.5%, 1.0%, 2.0%, 2.5%, 5%, 7.5%, 10%, 15%, 20%, or 25% with respect to the initially determined value prior to storage.The compositions according to these methods may be defined in accordance with any orcombination of embodiments of compositions as described herein above.In a yet a further aspect, the pharmaceutical compositions according to the present disclosureare useful or are provided as a medicine, for use in the treatment or prevention of disease ormedical conditions, preferably of a human subjects, or optionally, veterinary subjects; and in the manufacture of a medicament.In some embodiments, the composition is a topical ophthalmic composition, or in otherwords, a composition which may be topically applied or administered to the surface of asubject’s eye, or tissues associated with the eye, such as to the cornea or conjunctiva of theeye, or to the cul-de-sac of the conjunctiva. In a related embodiment, said composition is inthe form of a clear solution. In another embodiment, the pharmaceutical composition is formulated or adapted for intravitreal, subcutaneous, intramuscular injection, or for intravenous injection or infusion. In yet another embodiment, the composition is adapted fortopical administration to a surface of a tissue or organ, e.g. the skin or a mucosal tissue, forexample in relation to the eye. In one embodiment, the composition according to any one or combination of embodiments according to the present disclosure is used for the treatment, and / or prevention of an ophthalmic disease or condition, e.g. affecting one or both eyes of a subject. The use of a pharmaceutical composition as described in any one of the above embodiments in the manufacture or preparation of a medicament or a medicine for the treatment of a subject in need thereof in relation to any one of the disease or medical conditions described herein is also provided for in the context of the present disclosure. Further provided forwithin the context of the present disclosure, are also methods of treating subjects with, orsuffering from any medical conditions or disorders described herein; or methods of preventing or ameliorating medical conditions or disorders in said subjects, wherein said methods may comprise a step of administering (e.g. topical, e.g. topical ophthalmic administration) a composition as described herein to said subject.In yet another aspect, the present disclosure relates to a kit comprising a compositionaccording to any one or combination of embodiments described herein, a container adapted for holding the composition and optionally a means for dispensing the composition and / or instructions for use, wherein the instructions for use comprise any one of the uses or methods of treatment as described herein. The present disclosure comprises the following items :1. A liquid pharmaceutical composition comprising an enantiomer of a pharmaceuticallyactive compound or a pharmaceutically acceptable salt thereof, wherein the enantiomer is present in the composition in an enantiomeric excess of at least 78%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 93%, 96%, 97%,98% or 99%, and wherein the enantiomer is dissolved or suspended in a semifluorinated alkane, or dissolved or suspended in a vehicle comprising of a semifluorinated alkane and one or more excipients, preferably wherein the enantiomer is selected from pharmaceutically active compounds 2a to 76a or from compounds 2b to 76b of Table 1.A liquid pharmaceutical composition comprising enantiomers of a pharmaceuticallyactive compound or a pharmaceutically acceptable salt thereof, wherein the ratio of the first enantiomer relative to the second enantiomer is at least 89:11, 90:10, 91:8, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 or at least 99:1, wherein the enantiomers are dissolved or suspended in a semifluorinated alkane; or are dissolved or suspended in a vehicle comprising a semifluorinated alkane and one or more excipients, preferably wherein the enantiomer is selected from the pharmaceutically active compounds 2a to 76a or from compounds 2b to 76b of Table 1.The pharmaceutical composition according to item 1 or 2, wherein the compoundcomprises a chiral stereocenter on a carbon atom, wherein at least one of thesubstituents of the chiral stereocenter is i) a hydrogen moiety prone to deprotonationunder basic conditions and / or ii) is an alcohol moiety prone to dehydration under acidic conditions.The pharmaceutical composition according to item 1 to 3, wherein the enantiomer, orthe first enantiomer is selected from the list consisting of (S)-abediterol (2a), (R)- albuterol (levalbuterol) (3a), (S)-amlodipine (levamlodipine) (4a), levoamphetamine (5a), (S)-atomoxetine (6a), levobetaxolol ((S)-betaxolol) (7a), (R)-bicalutamide (8a), levobunolol (9a), (S)-bupivacaine (levbupivacaine) (10a), levocabastine (11a), (S)- carteolol (12a), levocetirizin (13a), dexchlorpheniramine (14a), (S)-chlorpheniramine (dexchlorpheniramine) (15a), (S)-citalopram (escitalopram) (16a), (S)-cromoglicic acid (17a), (S)-dipivefrine (18a), (-)-dobutamine (19a), (R)-doxylamine (20a), (S)- duloxetine (21a), (-)-erythro-mefloquin (22a), levoketoconazole (23a), dexfenfluramine (24a), (R)-fenoldopam (25a), (-)-gusperimus (deoxyspergualin) (26a), (R)-lansoprazole (dexlansoprazole) (27a), (S)-lenalidomide (28a), levoleucovorin (29a), linezolid (S-isomer) (30a), (R)-lipoic acid (31a), (R)- mebeverine (32a), dexmedetomidine (33a), levomethadone (34a), L- methamphetamine (levmetamfetamine) (35a), (S)-methotrexate (36a), D- methylphenidate (dexmethylphenidate) (37a), (S)-metipranolol (38a), L-milnacipran (levomilnacipran) (39a), (R)-modafinil) (armodafinil) (40a), (S)-naproxen (41a), levonorgestrel (42a), (S)-omeprazole (esomeprazole) (43a), L-ormeloxifene (levormeloxifene) (44a), levoprotiline (45a), (R)-oxybutynin (46a), dexpanthenol (47a), (S)-pheniramine malleate (48a), (S)-pindolol (49a), (R)-pioglitazone (50a), (R)- pralatrexate (51a), (S)-procyclidine (52a), levo-epinephrine (53a), ropivacaine (S- isomer) (54a), (-)-rotigotine (55a), (R)-ruxolitinib (56a), (R)-salbutamol (levosalbutamol) (57a), L-scopolamine (58a), (R)-tedizolid (59a), (R)-thalidomide (60a), (+)-tramadol (61a), (+)-tranylcypromine (62a), (-)-trihexylphenidyl (63a), (R)- tropicamide (64a), (S)-valsartan (65a), L-verapamil (66a), (S)-vigabatrin (67a), (S)- warfarin (68a), (S)-zopiclone (eszoplicone) (69a), (R)-STX478 (70a), (2R,5S)- ritlecitinib (71a), (3S,4R)-delgocitinib (72a), (3R,4R)-tofacitinib (73a), 4-[(1R)-1- Phenylethyl]-1,3-benzenediol (74a), (2S)-3-phenyl-2-(undec-10- enoylamino)propanoic acid (75a) and (S)-equol (76a).The pharmaceutical composition according to items 1 to 4, wherein the secondenantiomer is selected from the list consisting of (R)-abediterol (2b), (S)-albuterol (3b), (R)-amlodipine (4b), dextroamphetamine (5b), (R)-atomoxetine (6b), (R)- betaxolol (7b), (S)-bicalutamide (8b), dextrobunolol (9b), (R)-bupivacaine (10b), dextrocabastine (11b), (R)-carteolol (12b), dextrocetirizin (13b), (-)- chlorpheniramine (14b), (R)-chlorpheniramine (15b), (R)-citalopram (16b), (R)- cromoglicic acid (17b), (R)-dipivefrine (18b), (+)-dobutamine (19b), (S)-doxylamine (20b), (R)-duloxetine (21b), (+)-erythro-mefloquin (22b), dextroketoconazole (23b), levofenfluramine (24b), (S)-fenoldopam (25b), (+)-gusperimus (26b), (S)- lansoprazole (27b), (R)-lenalidomide (28b), dexleucovorin (29b), (R)-linezolid (30b), (S)-lipoic acid (31b), (S)-mebeverine (32b), levomedetomidine (33b), dexmethadone (34b), D-methamphetamine (dextromethamphetamine) (35b), (R)-methotrexate (36b), L-methylphenidate (37b), (R)-metipranolol (38b), D-milnacipran (levomilnacipran) (39b), (S)-modafinil (40b), (R)-naproxen (41b), dexnorgestrel (42b), (R)-omeprazole (43b), D-ormeloxifene (44b), dextroprotiline (45b), (S)- oxybutynin (46b), levopanthenol (47b), (R)-pheniramine malleate (48b), (R)-pindolol (49b), (S)-pioglitazone (50b), (S)-pralatrexate (51b), (R)-procyclidine (52b), dextro- epinephrine (53b), (R)-ropivacaine (54b), (+)-rotigotine (55b), (S)-ruxolitinib (56b), (S)-salbutamol (57b), D-scopolamine (58b), (S)-tedizolid (59b), (S)-thalidomide (60b), (-)-tramadol (61b), (-)-tranylcypromine (62b), (+)-trihexylphenidyl (63b), (S)- tropicamide (64b), (R)-valsartan (65b), D-verapamil (66b), (R)-vigabatrin (67b), (R)- warfarin (68b), (R)-zopiclone (eszoplicone) (69b), (S)-STX478 (70b), (2S,5R)- ritlecitinib (71b), (3R,4S)-delgocitinib (72b), (3S,4S)-tofacitinib (73b), 4-[(1S)-1- Phenylethyl]-1,3-benzenediol (74b), (2R)-3-phenyl-2-(undec-10- enoylamino)propanoic acid (75b) and (R)-equol (76b).The composition according to items 1 to 5, wherein the semifluorinated alkane isselected from the group consisting of F4H5, F4H6, F6H4, F6H6, F6H8, F6H10, their structural isomers and any combinations thereof.The composition according to items 1 to 6, wherein the semifluorinated alkane isselected from the group consisting of F4H5, F4H6, F6H4, F6H6, F6H10, their structural isomers and any combinations thereof.The composition according to item 7, wherein the semifluorinated alkane is selectedfrom the group consisting of F4H5 (1-perfluorobutyl-pentane), F6H8 (1- perfluorohexyl-octane), their structural isomers and any combinations thereof, preferably wherein the semifluorinated alkane is a combination of F4H5 (1- perfluorobutyl-pentane) and 2-perfluorobutyl-pentane.The composition according to item 8, wherein the semifluorinated alkane is 1-perfluorobutyl-pentane, and optionally 2-perfluorobutyl-pentane, wherein the 2-perfluorobutyl-pentane is present in an amount of up to 2 % (w / w), or up to 1 % (w / w), or up to 0.5 % (w / w) or up to 0.2 % (w / w in respect of the total weight of the mixture of semifluorinated alkanes.The composition according to item 9, wherein the semifluorinated alkane is 1-perfluorohexyl-octane, and optionally 2-perfluorohexyl-octane, wherein the 2-perfluorohexyl-octane is present in an amount of up to 2 % (w / w), or up to 1 % (w / w), or up to 0.5 % (w / w) in respect of the total weight of the mixture of semifluorinated alkanes.The pharmaceutical composition according to items 1 to 10, wherein the vehicleconsists of the semifluorinated alkane, or a mixture of semifluorinated alkanes.The composition according to items 1 to 11, wherein the semifluorinated alkane orsemifluorinated alkanes is / are present in an amount of at least 90%, 95%, 96%, 97%, 98%, 99% (w / w), based on the total weight of the composition.The composition according to items 1 to 12, wherein the semifluorinated alkane is 1-perfluorobutyl-pentane (F4H5) and is present in an amount of at least 90%, 95%, 96%, 97%, 98%, 99% (w / w), based on the total weight of the composition.The composition according to items 1 to 12, wherein the semifluorinated alkane is a1-perfluorobutyl-pentane (F4H5), and optionally also 2-perfluorobutyl-pentane and is / are present in an amount of at least 90%, 95%, 96%, 97%, 98%, 99% (w / w), based on the total weight of the composition.The composition according to any preceding item wherein the vehicle comprises orconsists of the semifluorinated alkane and one or more excipients, wherein the one or more excipients is selected from: a) a co-solvent, optionally wherein the co-solvent is an alcohol; preferably wherein the alcohol is selected from ethanol, 1-propanol, isopropanol, and phenylethyl alcohol; or more preferably wherein the alcohol is selected from ethanol and phenylethyl alcohol; b) an oily excipient, optionally wherein the oily excipient is selected from triglycerides, mineral oil, and liquid paraffin; preferably, wherein the oily excipient is selected from medium chain triglycerides (MCT) and light liquid paraffin; and c) any combination of a co-solvent or oily excipient as defined in a) or b).The composition according to any preceding item, wherein the vehicle consists of asemifluorinated alkane, and optionally a structural isomer thereof, and one or more excipients, wherein the one or more excipient is not an alcohol, and / or is not mediumchain triglycerides (MCT) and / or is not light liquid paraffin.The composition according to any preceding item, wherein the one or more excipientsis present in an amount of up to 0.1 %, 0.5 wt%, 0.75 wt%, 1.0 wt%, 1.25 wt%, 1.4 wt%, 1.5 wt%, 1.8 wt%, 2.0 wt%, 3.0 wt%, 4.0 wt% or up to 5.0 wt% (w / w), preferably up to 1 wt% or up to 1.4 wt%, based on the total weight of the composition.The pharmaceutical composition according to any preceding item, wherein thecomposition is formulated or adapted for intravitreal, subcutaneous, intramuscular injection, or for intravenous injection or infusion; or for topical administration to a surface of a tissue or organ, e.g. the skin.The pharmaceutical composition according to any preceding item for use as amedicine.The composition for use according to item 19, for use in the treatment or preventionof an ophthalmic disease or disorder.A kit comprising a composition according to any preceding item, the kit comprising acontainer adapted for holding the composition and optionally a means for dispensing the composition and / or instructions for use.A method of stabilizing, preventing, or reducing the loss of enantiomeric excess of anenantiomer of a pharmaceutically active compound, or a pharmaceutically acceptable salt thereof in a liquid composition, wherein the method comprises a step of dissolving or suspending the enantiomer in a semifluorinated alkane, or in a vehicle comprising a semifluorinated alkane and one or more excipients.The method according to item 22, wherein the enantiomeric excess of the enantiomerin the liquid composition is at least 78%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%,88%, 89%, 90%, 91%, 93%, 96%, 97%, 98% or 99% (e.g. by HPLC).A method of stabilizing, preventing, or reducing the loss of enantiomeric ratio withrespect to enantiomers of a pharmaceutically active compound or a pharmaceutically acceptable salt thereof in a liquid composition, wherein the method comprises a step of dissolving or suspending the enantiomers (or a mixture of two enantiomers) in a semifluorinated alkane, or in a vehicle comprising a semifluorinated alkane and one or more excipients, preferably wherein the enantiomers (or mixture of two enantiomers) comprise a first enantiomer and a second enantiomer.The method according to item 24, wherein the ratio of the first enantiomer relative tothe second enantiomer is at least 89:11, 90:10, 91:8, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 or at least 99:1A method of stabilizing, preventing, or reducing the loss stereochemical orenantiomeric purity of an enantiomer of a pharmaceutically active compound, or apharmaceutically acceptable salt thereof in a liquid composition, wherein the method comprises a step of dissolving or suspending the enantiomer in a semifluorinatedalkane, or in a vehicle comprising a semifluorinated alkane and one or moreexcipients.The method according to item 26, wherein the purity of the enantiomer in thecomposition is at least 90% or at least 95% or at least 97% (e.g. by HPLC).The method according to items 24 to 27, wherein the enantiomer, or the firstenantiomer comprises a chiral stereocenter on a carbon atom, wherein at least one of the substituents of the chiral stereocenter is i) a hydrogen moiety prone to deprotonation under basic conditions and / or ii) is an alcohol moiety prone to dehydration under acidic conditions; and / or is susceptible to racemization, isomerization or epimerization.The method according to items 22 to 28, wherein the enantiomer or first, or secondenantiomer is selected from the list consisting of (S)-abediterol (2a), (R)-albuterol (levalbuterol) (3a), (S)-amlodipine (levamlodipine) (4a), levoamphetamine (5a), (S)- atomoxetine (6a), levobetaxolol ((S)-betaxolol) (7a), (R)-bicalutamide (8a), levobunolol (9a), (S)-bupivacaine (levbupivacaine) (10a), levocabastine (11a), (S)- carteolol (12a), levocetirizin (13a), dexchlorpheniramine (14a), (S)-chlorpheniramine (dexchlorpheniramine) (15a), (S)-citalopram (escitalopram) (16a), (S)-cromoglicic acid (17a), (S)-dipivefrine (18a), (-)-dobutamine (19a), (R)-doxylamine (20a), (S)- duloxetine (21a), (-)-erythro-mefloquin (22a), levoketoconazole (23a), dexfenfluramine (24a), (R)-fenoldopam (25a), (-)-gusperimus (deoxyspergualin) (26a), (R)-lansoprazole (dexlansoprazole) (27a), (S)-lenalidomide (28a), levoleucovorin (29a), linezolid (S-isomer) (30a), (R)-lipoic acid (31a), (R)- mebeverine (32a), dexmedetomidine (33a), levomethadone (34a), L- methamphetamine (levmetamfetamine) (35a), (S)-methotrexate (36a), D- methylphenidate (dexmethylphenidate) (37a), (S)-metipranolol (38a), L-milnacipran (levomilnacipran) (39a), (R)-modafinil) (armodafinil) (40a), (S)-naproxen (41a),levonorgestrel (42a), (S)-omeprazole (esomeprazole) (43a), L-ormeloxifene(levormeloxifene) (44a), levoprotiline (45a), (R)-oxybutynin (46a), dexpanthenol (47a), (S)-pheniramine malleate (48a), (S)-pindolol (49a), (R)-pioglitazone (50a), (R)- pralatrexate (51a), (S)-procyclidine (52a), levo-epinephrine (53a), ropivacaine (S- isomer) (54a), (-)-rotigotine (55a), (R)-ruxolitinib (56a), (R)-salbutamol (levosalbutamol) (57a), L-scopolamine (58a), (R)-tedizolid (59a), (R)-thalidomide (60a), (+)-tramadol (61a), (+)-tranylcypromine (62a), (-)-trihexylphenidyl (63a), (R)- tropicamide (64a), (S)-valsartan (65a), L-verapamil (66a), (S)-vigabatrin (67a), (S)- warfarin (68a), (S)-zopiclone (eszoplicone) (69a), (R)-STX478 (70a), (2R,5S)- ritlecitinib (71a), (3S,4R)-delgocitinib (72a), (3R,4R)-tofacitinib (73a), 4-[(1R)-1- Phenylethyl]-1,3-benzenediol (74a), (2S)-3-phenyl-2-(undec-10- enoylamino)propanoic acid (75a) and (S)-equol (76a).The method according to items 22 to 31, wherein the enantiomer, first, or secondenantiomer is selected from the list consisting (R)-abediterol (2b), (S)-albuterol (3b),(R)-amlodipine (4b), dextroamphetamine (5b), (R)-atomoxetine (6b), (R)-betaxolol (7b), (S)-bicalutamide (8b), dextrobunolol (9b), (R)-bupivacaine (10b), dextrocabastine (11b), (R)-carteolol (12b), dextrocetirizin (13b), (-)- chlorpheniramine (14b), (R)-chlorpheniramine (15b), (R)-citalopram (16b), (R)-cromoglicic acid (17b), (R)-dipivefrine (18b), (+)-dobutamine (19b), (S)-doxylamine (20b), (R)-duloxetine (21b), (+)-erythro-mefloquin (22b), dextroketoconazole (23b), levofenfluramine (24b), (S)-fenoldopam (25b), (+)-gusperimus (26b), (S)- lansoprazole (27b), (R)-lenalidomide (28b), dexleucovorin (29b), (R)-linezolid (30b), (S)-lipoic acid (31b), (S)-mebeverine (32b), levomedetomidine (33b), dexmethadone (34b), D-methamphetamine (dextromethamphetamine) (35b), (R)-methotrexate (36b), L-methylphenidate (37b), (R)-metipranolol (38b), D-milnacipran(levomilnacipran) (39b), (S)-modafinil (40b), (R)-naproxen (41b), dexnorgestrel(42b), (R)-omeprazole (43b), D-ormeloxifene (44b), dextroprotiline (45b), (S)- oxybutynin (46b), levopanthenol (47b), (R)-pheniramine malleate (48b), (R)-pindolol (49b), (S)-pioglitazone (50b), (S)-pralatrexate (51b), (R)-procyclidine (52b), dextro- epinephrine (53b), (R)-ropivacaine (54b), (+)-rotigotine (55b), (S)-ruxolitinib (56b), (S)-salbutamol (57b), D-scopolamine (58b), (S)-tedizolid (59b), (S)-thalidomide (60b), (-)-tramadol (61b), (-)-tranylcypromine (62b), (+)-trihexylphenidyl (63b), (S)- tropicamide (64b), (R)-valsartan (65b), D-verapamil (66b), (R)-vigabatrin (67b), (R)- warfarin (68b), (R)-zopiclone (eszoplicone) (69b), (S)-STX478 (70b), (2S,5R)- ritlecitinib (71b), (3R,4S)-delgocitinib (72b), (3S,4S)-tofacitinib (73b), 4-[(1S)-1- Phenylethyl]-1,3-benzenediol (74b), (2R)-3-phenyl-2-(undec-10- enoylamino)propanoic acid (75b) and (R)-equol (76b).The method according to items 24 to 30, wherein after storage of the composition fora period of at least 1, 2, 3, 4, 5, 6, 9 or 12 months at 0 to 60 °C (e.g. at 25 °C),i) the concentration of the enantiomer is essentially the same, or has notchanged or decreased by more than 10%, more than 5%, more than 4%, morethan 3%, more than 2%, more than 1% or more than 0.5% (e.g. as determinedby HPLC) with respect to its initial concentration in the composition prior tostorage; and / orii) the enantiomeric excess of the enantiomer, or the first enantiomer isessentially the same, or has not changed or decreased by more than 10%, more than 5%, more than 4%, more than 3%, more than 2%, more than 1% ormore than 0.5% with respect to the initially determined value prior tostorage; and / oriii) the enantiomeric ratio of the first enantiomer with respect to the secondenantiomer is the same, or has not decreased 0.5%, 1.0%, 2.0%, 2.5%, 5%, 7.5%, 10%, 15%, 20%, or 25% with respect to the initially determined value prior to storage.32. The method according to items 22 to 31, wherein the composition is as defined inaccordance with any one or combination of items 1 to 17. EXAMPLES Example 1Hyoscyamine solutions were prepared in F4H5 (1-perfluorobutylpentane) or in 1% (v / v) 2-propanol in 1-perfluorobutylpentane.The (S)-hyoscyamine, or atropine (racemic mixture of (S)-hyoscyamine and (R)-hyoscyamine; CAS 5908-99; EDQM, Y0000878) was weighed into 1.5 mL vials. F4H5, or F4H5 with 1 % (v / v) 2-propanol was then added to the vials, and the resulting mixture was stirred overnight at 300 rpm to provide clear solutions.The (S)-hyoscyamine used (CAS 101-31-5; Abcam Pharmatech, Changzhou, China)comprised of 90.8% (S)-hyoscyamine and 9.2% (R)-hyoscyamine, i.e. an enantiomeric excess(ee) of 81.6% of (S)-hyoscyamine, or an enantiomeric ratio of (S)-hyoscyamine to (R)-hyoscyamine of about 9.87.The following solutions were prepared:(1) 0.1 mg / mL atropine in 1% (v / v) 2-Propanol in F4H5 (i.e. a solution comprising 0.05 mg / ml (S)-hyoscyamine) (2): 0.4 mg / ml atropine in 1% (v / v) 2-Propanol in F4H5 (i.e. a solution comprising 0.2 mg / ml (S)-hyoscyamine)(3) 0.1 mg / mL (S)-hyoscyamine in F4H5(4) 0.1 mg / mL (S)-hyoscyamine in 1% (v / v) 2-propanol in F4H5.(5) 0.05 mg / mL (S)-hyoscyamine in 1% (v / v) ethanol in F4H5.(6) 0.05 mg / mL (S)-hyoscyamine in 1% (v / v) ethanol in F6H8.HPLC was using a chiral HPLC column (Lux Cellulose-2; Phenomenex) to simultaneouslydetect (R)- and (S)-hyoscyamine enantiomers in these solutions. As shown in Figure 1, thetwo enantiomers are clearly distinguishable (see Figure 1). Example 2The solutions of 0.1 mg / mL (S)-hyoscyamine in 1% (v / v) 2-propanol in F4H5 and 0.1 mg / mL(S)-hyoscyamine in F4H5, as prepared according to Example 1, are checked for stability andfor the racemization of (S)-hyoscyamine during storage at room temperature (25°C).It was found that the ratio of (S)-to (R)-hyoscyamine in the injected solutions did not changemore than 0.2% over 5 days for the 0.1 mg / mL solution in F4H5 + 1% (v / v) 2-propanol andrespectively 4 days in a 0.1 mg / ml solution in F4H5 without 2-propanol. Continuing the stability study at room temperature (25°C) for 1.5 months confirmed that theratio of (S)-to (R)-hyoscyamine in these compositions was unchanged, demonstrating theimproved shelf-life of the (S)-hyoscyamine compositions.The stability of the solutions at elevated temperature is also tested.A solution of 0.1 mg / mL (S)-hyoscyamine in 1% (v / v) 2-propanol in F4H5, and solution of 0.1mg / ml solution in F4H5, was heated at 60°C for 1 hour. HPLC analysis to check the stability ofthe solution and for racemization revealed that the initial enantiomeric purity of 90.8% of(S)-hyoscyamine was maintained in both solution formulations, and that no otherdegradation products were produced. This demonstrated that compositions comprising (S)-hyoscyamine and semifluorinated alkanes are stable at the experimental conditions and doesnot undergo racemization or degradation, even at the elevated temperature.Example 3The stability of solutions of 0.05 mg / ml (S)-hyoscyamine (1a) in F4H5, 0.05 mg / ml (S)-hyoscyamine in F6H8 and 0.10 mg / ml atropine in F4H5 was monitored at room temperature(25°C) over a period of 6 months. It was shown that the ratio of the two enantiomers (i.e. (R)-to (S)-hyoscyamine enantiomeric ratio) as measured by HPLC on the basis of peak area waseffectively stable over this period, with no isomerization and change in the enantiomericratio. It was shown that the enantiomeric excess of S-hyoscyamine (1a), both in F4H5 andF6H8, was stable at 94%ee over the period of 6 months:Sample (S)- / ^(R)-hyoscyamine (1a^ (S)- / ^(R)-hyoscyamine (1a^ / ^1b)- enantiomeric^ratio / ^1b)^enantiomeric^ratio t=0 t=6^months 0.05 mg / mL (S)-hyoscyamine inF4H5 97 / 3 3 / 97 0.05 mg / mL (S)-hyoscyamine inF6H8 97 / 3 97 / 3 0.10 mg / mL atropine in F4H5 51 / 49 51 / 49Example 4A solution or a suspension of any one of the enantiomeric compounds (2a to 76a, 2b to 76b)as featured in Table 1 herein (Column A, or Column B) in a semifluorinated alkane (e.g. F6H8,or F4H5), or a vehicle comprising a semifluorinated alkane (e.g. F6H8, or F4H5) andoptionally one or more excipients as described herein are prepared according to the generalmethod as follows:Weighing an amount of the compound into a container e.g. a vial, and adding asemifluorinated alkane, or a semifluorinated alkane in mixture with one or more excipients, to the container to obtain a desired concentration of the compound in the composition andthen processing, for example by stirring so as to provide the solution, or the suspension.The enantiomeric excess or ratio of the enantiomer(s) of the compound in the composition isdetermined, e.g. by chiral HPLC on the basis of peak area, or by another suitable analyticalmethod capable for quantifying optical active compounds, such as enantiomers. Thecomposition is then subjected to aging conditions over a period of time (for example, 2weeks, or 1 month, or up to 6 months) to determine the stability of the compound in thecomposition, and for racemization, or loss of stereochemical purity; optionally during, or atthe end of this period of time. The stability and percentage of the enantiomer(s) in thecomposition is measured by sampling the composition and performing e.g. chiral HPLC on thebasis of peak area or using the same analytical method utilized to determine compoundpurity in the composition at the start of the study.It is expected that the initial enantiomeric purity (such as enantiomeric excess, enantiomeric ratio) of the compound is essentially maintained in the formulations in the semifluorinatedalkane or vehicle with minimal formation of degradation products, racemization, or change inenantiomeric purity of the enantiomer, demonstrating that the semifluorinated alkane mayprovide a stable vehicle or formulation for liquid compositions of the enantiomeric compound. Example 5A solution of (R)-ruxolitinib (56a in Table 1) in a vehicle comprising F6H8 and optionally oneor more excipients was prepared, as described in Example 4.The enantiomeric excess of (R)-ruxolitinib (56a) or the ratio of the enantiomer(s) (R)-ruxolitinib (56a) vs (S)-ruxolitinib (56b)) in the composition is determined by chiral HPLC onthe basis of peak area. The composition is then subjected to aging conditions over a period of time (for example, 2 weeks, or 1 month, or up to 6 months) to determine the stability of (R)-ruxolitinib (56a) in the composition, and for racemization, or loss of stereochemical purity.It is expected that the initial enantiomeric purity (such as enantiomeric excess, enantiomericratio) of (R)-ruxolitinib (56a) is essentially maintained in the solution of (R)-ruxolitinib (56a)dissolved in the vehicle comprising F6H8 and optionally one or more excipients, withminimal conversion to degradation products or racemization to (S)-ruxolitinib (56b), orchanges in enantiomeric purity of the compound in the composition, demonstrating that F6H8 may provide a stable vehicle or formulation for liquid compositions of (R)-ruxolitinib (56a).

Claims

NVL24P01PC1 Claims1. A liquid pharmaceutical composition comprising an enantiomer of a pharmaceuticallyactive compound or a pharmaceutically acceptable salt thereof, wherein the enantiomer is present in the composition in an enantiomeric excess of at least 78%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 93%, 96%, 97%, 98% or 99%, and wherein the enantiomer is dissolved or suspended in a semifluorinated alkane, or dissolved or suspended in a vehicle comprising of a semifluorinated alkane and one or more excipients, wherein the enantiomer is (R)-ruxolitinib (56a).

2. A liquid pharmaceutical composition comprising enantiomers of a pharmaceuticallyactive compound or a pharmaceutically acceptable salt thereof, wherein the ratio of the first enantiomer relative to the second enantiomer is at least 89:11, 90:10, 91:8, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 or at least 99:1, wherein the enantiomers are dissolved or suspended in a semifluorinated alkane; or are dissolved or suspended in a vehicle comprising a semifluorinated alkane and one or more excipients, wherein the first enantiomer is (R)-ruxolitinib (56a) and wherein the second enantiomer is(S)-ruxolitinib (56b).

3. The composition according to claims 1 to 2, wherein the semifluorinated alkane isselected from the group consisting of F4H5, F4H6, F6H4, F6H6, F6H8, F6H10, their structural isomers and any combinations thereof.

4. The composition according to claims 1 to 3, wherein the semifluorinated alkane isselected from the group consisting of F4H5 (1-perfluorobutyl-pentane), F6H8 (1-perfluorohexyl-octane), their structural isomers and any combinations thereof.

5. The composition according to claims 1 to 4, wherein the semifluorinated alkane is 1-perfluorobutyl-pentane, and optionally 2-perfluorobutyl-pentane, wherein the 2-perfluorobutyl-pentane is present in an amount of up to 2 % (w / w), or up to 1 % (w / w), or up to 0.5 % (w / w) or up to 0.2 % (w / w in respect of the total weight of the mixture of semifluorinated alkanes.

6. The composition according to claims 1 to 4, wherein the semifluorinated alkane is 1-perfluorohexyl-octane, and optionally 2-perfluorohexyl-octane, wherein the 2-perfluorohexyl-octane is present in an amount of up to 2 % (w / w), or up to 1 %(w / w), or up to 0.5 % (w / w) in respect of the total weight of the mixture of semifluorinated alkanes.

7. The pharmaceutical composition according to claims 1 to 6, wherein the vehicleconsists of the semifluorinated alkane, or a mixture of semifluorinated alkanes.

8. The composition according to claims 1 to 7, wherein the semifluorinated alkane orsemifluorinated alkanes is / are present in an amount of at least 90%, 95%, 96%, 97%,98%, 99% (w / w), based on the total weight of the composition.

9. The composition according to claims 1 to 8, wherein the semifluorinated alkane is 1-perfluorobutyl-pentane (F4H5) and is present in an amount of at least 90%, 95%, 96%, 97%, 98%, 99% (w / w), based on the total weight of the composition.

10. The composition according to claims 1 to 8, wherein the semifluorinated alkane is 1-perfluorobutyl-pentane (F4H5), and optionally also 2-perfluorobutyl-pentane andis / are present in an amount of at least 90%, 95%, 96%, 97%, 98%, 99% (w / w), basedon the total weight of the composition.

11. The composition according to claims 1 to 8, wherein the semifluorinated alkane is 1-perfluorohexyl-octane (F6H8), and optionally 2-perfluorohexyl-octane and is / are present in an amount of at least about 90%, 95% 96%, 97%, 98%, 99% or at least 99.5% (w / w) based on the total weight of the pharmaceutical composition.

12. The composition according to claims 1 to 8, wherein the semifluorinated alkane is a 1-perfluorohexyl-octane (F6H8), and optionally also 2-perfluorohexyl-octane and is / are present in an amount of at least 90%, 95%, 96%, 97%, 98%, 99% (v / v), based on the total volume of the composition.

13. The composition according to any preceding claim wherein the vehicle comprises orconsists of the semifluorinated alkane and one or more excipients, wherein the one or more excipients is selected from: a) a co-solvent, optionally wherein the co-solvent is an alcohol; preferably whereinthe alcohol is selected from ethanol, 1-propanol, isopropanol, and phenylethyl alcohol; or more preferably wherein the alcohol is selected from ethanol andphenylethyl alcohol; b) an oily excipient, optionally wherein the oily excipient is selected from triglycerides, mineral oil, and liquid paraffin; preferably, wherein the oily excipient is selected from medium chain triglycerides (MCT) and light liquid paraffin; andc) any combination of a co-solvent or oily excipient as defined in a) or b).

14. The composition according to any preceding claim, wherein the vehicle consists of asemifluorinated alkane, and optionally a structural isomer thereof, and one or moreexcipients, wherein the one or more excipient is not an alcohol, and / or is not medium chain triglycerides (MCT) and / or is not light liquid paraffin.

15. The composition according to any preceding claim, wherein the one or moreexcipients is present in an amount of up to 0.1 %, 0.5 wt%, 0.75 wt%, 1.0 wt%, 1.25wt%, 1.4 wt%, 1.5 wt%, 1.8 wt%, 2.0 wt%, 3.0 wt%, 4.0 wt% or up to 5.0 wt% (w / w), preferably up to 1 wt% or up to 1.4 wt%, based on the total weight of the composition.

16. The pharmaceutical composition according to any preceding claim, wherein thecomposition is formulated or adapted for intravitreal, subcutaneous, intramuscular injection, or for intravenous injection or infusion; or for topical administration to asurface of a tissue or organ, e.g. the skin.

17. The pharmaceutical composition according to any preceding claim for use as amedicine.

18. The composition for use according to claim 17, for use in the treatment or preventionof an ophthalmic disease or disorder.

19. A kit comprising a composition according to any preceding claim, the kit comprising acontainer adapted for holding the composition and optionally a means for dispensing the composition and / or instructions for use.

20. A method of stabilizing, preventing, or reducing the loss of enantiomeric excess of anenantiomer of a pharmaceutically active compound, or a pharmaceutically acceptable salt thereof in a liquid composition, wherein the method comprises a step of dissolving or suspending the enantiomer in a semifluorinated alkane, or in a vehicle comprising a semifluorinated alkane and one or more excipients, wherein theenantiomer is (R)-ruxolitinib (56a).

21. The method according to claim 20, wherein the enantiomeric excess of theenantiomer in the liquid composition is at least 78%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 93%, 96%, 97%, 98% or 99% (e.g. by HPLC).

22. A method of stabilizing, preventing, or reducing the loss of enantiomeric ratio withrespect to enantiomers of a pharmaceutically active compound or a pharmaceuticallyacceptable salt thereof in a liquid composition, wherein the method comprises a stepof dissolving or suspending a mixture of two enantiomers in a semifluorinated alkane,or in a vehicle comprising a semifluorinated alkane and one or more excipients,wherein the mixture of two enantiomers is (R)-ruxolitinib (56a) and (S)-ruxolitinib(56b).

23. The method according to claim 22, wherein the ratio of the first enantiomer relativeto the second enantiomer is at least 89:11, 90:10, 91:8, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2 or at least 99:1.

24. A method of stabilizing, preventing, or reducing the loss stereochemical orenantiomeric purity of an enantiomer of a pharmaceutically active compound, or apharmaceutically acceptable salt thereof in a liquid composition, wherein the method comprises a step of dissolving or suspending the enantiomer in a semifluorinated alkane, or in a vehicle comprising a semifluorinated alkane and one or moreexcipients, wherein the enantiomer is (R)-ruxolitinib (56a).

25. The method according to claim 24, wherein the purity of the enantiomer in thecomposition is at least 90% or at least 95% or at least 97% (e.g. by HPLC).

26. The method according to claims 24 to 25, wherein after storage of the composition fora period of at least 1, 2, 3, 4, 5, 6, 9 or 12 months at 0 to 60 °C (e.g. at 25 °C),iv) the concentration of the enantiomer is essentially the same, or has notchanged or decreased by more than 10%, more than 5%, more than 4%, morethan 3%, more than 2%, more than 1% or more than 0.5% (e.g. as determinedby HPLC) with respect to its initial concentration in the composition prior tostorage; and / or v) the enantiomeric excess of the enantiomer, or the first enantiomer isessentially the same, or has not changed or decreased by more than 10%,more than 5%, more than 4%, more than 3%, more than 2%, more than 1% ormore than 0.5% with respect to the initially determined value prior tostorage; and / orvi) the enantiomeric ratio of the first enantiomer with respect to the secondenantiomer is the same, or has not decreased 0.5%, 1.0%, 2.0%, 2.5%, 5%, 7.5%, 10%, 15%, 20%, or 25% with respect to the initially determined value prior to storage.

27. The method according to claims 20 to 26, wherein the composition is as defined inaccordance with any one or combination of claims 1 to 16.

Images